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Introduction
In the ‘First Workshop on Pharmacology and 
Management of Cyclin-dependent kinase (CDK) 
4/6 inhibitors (CDK4/6i): Consensus about 
Concomitant Medications’, promoted by the 
Spanish Breast Cancer Cooperative Group 
SOLTI, medical oncologists specialized in breast 
cancer joined physicians specialized in pharma-
cology, cardiology, psychiatry, infectious dis-
eases, palliative care or radiation oncology in an 
interdisciplinary discussion forum, at Spanish 
national level, to address different issues regard-
ing patients treated with palbociclib and riboci-
clib. These issues included overall management 
of adverse events (AEs) of special interest, expert 
opinion about clinical situations for which evi-
dence of treatment with these drugs is limited, 
and, above all, concomitant medications that 
may be safely administered. This workshop was 
held on 22 May 2018. This article brings together 
the issues that were addressed, the information 
compiled and the conclusions of this 1-day 
meeting.
Drug–drug interactions (DDIs) are a common issue 
in clinical practice, particularly in the oncology set-
ting,1,2 but appear to be particularly relevant in the 
CDK4/6i scenario. Firstly, because the indication of 
palbociclib and ribociclib is expected to be massive 
in Spain and other countries where these drugs are 
marketed, given their high efficacy and overall good 
tolerability in patients with endocrine-sensitive, met-
astatic HER2-negative breast cancer. Secondly, and 
equally important, patients can receive CDK4/6i for 
long periods of time (median progression-free sur-
vival in first- and second-line therapy of about 2 
years and 9 months, respectively);3–6 this prolonged 
treatment time favours the emergence of other 
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clinical conditions that require concomitant drugs 
(e.g. infections, allergies, episodes of pain or depres-
sion). Thirdly, because there are slight differences 
between the pharmacological properties of palboci-
clib and ribociclib distinct recommendations have 
been made regarding DDIs and even in different tri-
als for the same CDK4/6i. The workshop’s organiz-
ing committee believed that this has generated, and 
still does, some confusion among oncologists and 
can lead to attitudes that are either too permissive, 
with the subsequent risk of relevant DDIs or, on the 
contrary, too conservative, which could lead to 
undertreating the patient’s comorbidity.
All three facts seem to warrant comprehensive train-
ing for oncologists. In this context, the aim was to 
thoroughly review the potential for DDIs with 
CDK4/6i, including putative synergy in corrected 
QT (QTc) prolongation, in order to provide oncol-
ogists with a reason to prohibit or prescribe certain 
medications with caution. Above all, the aim was to 
elaborate ‘positive lists’ of medications indicated for 
the most common comorbid conditions that could 
be safely administered with palbociclib or ribociclib. 
We were aware that such ‘positive’ information was 
not included in any clinical trial protocol nor could 
it be provided by pharmaceutical companies.
Moreover, the aim was to delve into different issues 
regarding CDK4/6i’s toxicity, which are consid-
ered of special interest including neutropaenia, 
QTc prolongation and transaminitis/liver toxicity. 
Evidence regarding such toxicities were thoroughly 
reviewed and discussed at the workshop.
Issues regarding toxicity or management, for which 
scarce or no evidence exists, were addressed by 
means of a questionnaire aimed to gather the expert 
opinion of participants who had been invited because 
of their experience with CDK4/6i in clinical trials.
Finally, the aim was to elaborate and publish a 
consensus document with the evidence-based 
information compiled during the workshop, as it 
was considered that this could be extremely helpful 
in the daily practice of oncologists dealing with 
CDK4/6i. This consensus document is presented 
here. It covers all parts of the workshop with the 
exception of the clinicians’ preferences determined 
by the survey, as we considered that the results 
were based on a limited number of participants.
Methodology
Oncology participants were selected and indi-
vidually invited to the workshop based on their 
recognized experience in managing CDK4/6i. 
Representatives of all Spanish regions and from 
two Spanish Breast Cancer Cooperative Groups 
(SOLTI and GEICAM) attended the meeting. 
Specialists from other disciplines were chosen 
because of their expertise in specific areas of 
interest related to patients with metastatic breast 
cancer (MBC) or CDK4/6i pharmacology or 
toxicity.
The workshop was organized in three parts.
Educational module: this included five lectures. 
Those regarding ‘Key Concepts on DDIs’, 
‘QT Evaluation and Management’ and 
‘Antidepressants’ were given by a hospital phar-
macist specialist with wide experience in DDI 
assessment, a cardiologist specialized in congeni-
tal and acquired QT-interval syndromes, and a 
psychiatrist working in an oncology department 
for many years, respectively. These were followed 
by two talks given by two medical oncologists 
with wide experience in ribociclib and palbociclib 
treatments, who addressed neutropaenia, infec-
tions, QTc prolongation, liver toxicity and other 
CDK4/6i-related toxicities. Extensive and collec-
tive pre-work was undertaken by the organizers to 
ensure that a comprehensive review and rigorous 
information was presented at the workshop.
Individual 15-min questionnaires: each ques-
tionnaire comprised 24 questions. Besides demo-
graphic data, participants were asked about 
preferred therapeutic strategy (chemotherapy 
(CT) versus endocrine therapy (ET) + CDK4/6i 
versus CT followed by maintenance ET + 
CDK4/6i) in challenging clinical conditions such 
as inflammatory breast cancer, myelophthisis, 
peritoneal carcinomatosis or pulmonary lym-
phangitis. They were also asked about adminis-
tration times of palbociclib/ribociclib regarding 
planned surgery and radiotherapy, reintroduc-
tion of CDK4/6i after recovered liver toxicity 
caused by one of them, and rare toxicities 
observed. The results of these questionnaires are 
not presented here.
Collaborative module: five working groups, each 
group made up of four or five experts from differ-
ent fields, were formed. Each group received a 
template (previously prepared by three medical 
oncologists and three hospital pharmacist special-
ists) that included guidelines and references to 
elaborate and appropriate positive lists of medica-
tions for particular clinical condition(s), which 
were specific for them. In addition, each working 
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group also received a PowerPoint presentation 
including: (a) a hypothetical clinical situation 
related to the group of medications assigned, 
which illustrated the risk for potential DDIs; (b) a 
template table to guide and unify the lists of med-
ications presented across all the working groups. 
Then, each group explained the results obtained 
to the whole audience, which were discussed to 
reach a consensus.
The workshop was sponsored mainly by Pfizer 
and Novartis. Although representatives of both 
companies indicated their willingness to attend 
the workshop, this was not allowed in order to 
prevent any interference with the workshop 
dynamics. Instead, the workshop organizers pro-
vided the companies’ representatives with a draft 
of the manuscript so they could add insights 
regarding literature missing from the document. 
The two companies made no relevant comments 
or suggestions during the 48 h allowed for review 
and, therefore, no changes were made to the 
manuscript.
Educational module
Drug metabolic pathways and membrane 
transporters: how to interpret DDIs with 
palbociclib and ribociclib?
Main pharmacokinetic DDIs are secondary to 
alterations in the enzymatic metabolism, mainly 
at the cytochrome p450 level. Other DDIs result 
from inhibition or induction of membrane trans-
porters, such as P-glycoprotein (P-gp) and 
organic anion transporters (OATs), which can be 
caused by some drugs. Several drugs are sub-
strates for membrane transporters, which mean 
that they depend, at any step, on this active trans-
port through the membranes to reach their site of 
action (process of absorption and distribution) or 
to be eliminated. These membrane transporters 
are proteins susceptible to being induced or inhib-
ited by some drugs, which, as a consequence, may 
increase or decrease the concentration of the 
transporter substrates in the organism.7,8
Absorption. At this level, drug interaction can 
affect either the bioavailability of the drug, the 
amount of drug absorbed or the rate of absorp-
tion. The most frequent interactions affecting 
absorption are due to gastric pH modification. 
This occurs with proton pump inhibitors (PPIs), 
antacids or H2-receptor antagonists. Chelation 
with calcium, iron or ionic resins can lead to 
the formation of nonabsorbable compounds, 
reducing the bioavailability of concomitant drugs. 
Finally, modification of intestinal motility can 
also alter the absorption process.
The solubility of palbociclib is significantly 
reduced at pH values greater than 4. 
Co-administration of rabeprazole and palbociclib 
under fasting conditions decreased the maximum 
concentration (Cmax) and the area under the con-
centration curve (AUC) by 62% and 80%, respec-
tively. However, when co-administered with food, 
Cmax and AUC decreased by 41% and 13%, 
respectively.9 Palbociclib therefore should be 
taken with food. It is expected that palbociclib 
absorption will not be affected by H2-receptor 
antagonists and local antacids.10
The highest solubility of ribociclib is at or below 
pH 4.5. DDIs are not expected with PPIs, 
H2-receptor antagonists or antacids.11 Ribociclib 
can be taken with or without food.12
Although palbociclib and ribociclib absorption 
does not seem to be affected by co-administration 
with antacids, the Summary of Product 
Characteristics (SPC) of most common antacids, 
such as magnesium hydroxide and amalgamate, 
recommends separating their intake for at least 2 
h from other drugs.13,14
Finally, palbociclib and ribociclib can cause diar-
rhoea as a side effect, which may affect the absorp-
tion of other drugs.
Distribution. Distribution-related DDIs are not 
expected because palbociclib and ribociclib are 
not highly protein bound (palbociclib 85% and 
ribociclib 70%).10,12
Metabolism. Metabolism includes all the mole-
cule reactions when partially or totally trans-
formed in other substances.15
When a drug is metabolized by a specific CYP 
isoenzyme, it is known as a substrate for that CYP 
isoenzyme. Several drugs have the potential to 
inhibit or induce different CYP isoenzymes with 
variable intensity, which impacts on the metabo-
lism of other drugs (Table S1, Supplementary 
material, File 1).
Taking into account the degree of dependence on 
a specific isoenzyme to be metabolized, substrates 
are classified as major (when they are mainly elimi-
nated by that isoenzyme) or minor substrates 
(Table S1, Supplementary material, File 1). 
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Moreover, the US Food and Drug Administration 
(FDA) distinguishes these other categories: sensi-
tive substrates (SS), when a substrate demon-
strates an increase in AUC of 5-fold or greater with 
strong index inhibitors; moderately sensitive sub-
strates, when the increase in AUC is 2-fold or 
greater to less than 5-fold, and narrow therapeutic 
index (NTI) substrates, when a substrate has a 
narrow index between the minimum effective con-
centration and the minimum toxic concentration. 
Therefore, small variations of drugs with NTI can 
cause either a loss of efficacy or toxicity.
Palbociclib and ribociclib are major substrates for 
CYP3A4 so, hereinafter, only CYP3A4 will be 
specifically mentioned.
Palbociclib is a weak inhibitor of CYP3A4, but in 
the SPC,10 a dose reduction in NTI substrates is 
suggested when concomitantly administered with 
palbociclib, since their exposure could be 
increased. By contrast, ribociclib is a strong 
CYP3A4 inhibitor when administered at a 600 
mg dose, and a moderate CYP3A4 inhibitor at a 
400 mg dose.12 Therefore, due to its intrinsic 
CYP3A4 inhibitory properties, ribociclib may 
lead to increased serum concentrations of 
CYP3A4 substrates in a more extensive way 
(Figure 1).
On the other hand, co-administration of palboci-
clib or ribociclib with strong or moderate CYP3A4 
inhibitors may increase the AUC of palbociclib or 
ribociclib and, consequently, their risk of toxicity. 
So, these CYP3A4 inhibitors should be avoided 
when possible. Co-administration of strong or 
moderate CYP3A4 inducers, on the contrary, 
may decrease exposure to palbociclib and riboci-
clib and lead to a lack of efficacy, so they also 
should be avoided. These recommendations are 
included in the SPC of both palbociclib and ribo-
ciclib.10,12 See Table 1 for recommendations and 
dose modification.
Membrane transporters. The role of membrane 
transporters, such as P-gp or breast cancer resis-
tance protein (BCRP), in the development of drug 
resistance has been observed in several studies.16,17 
The most studied membrane transporter, P-gp, is 
constitutively expressed in several normal human 
tissues, including the liver, kidney, small and large 
intestine, testes, adrenal gland and the placenta. It 
is also located in the endothelial cells of the blood-
brain barrier (BBB). This particular tissue distri-
bution indicates an important detoxification role 
for P-gp, and by extension, for many membrane 
transporters, by excreting xenobiotics and metab-
olites into urine, bile and the intestinal lumen.18 
Some cancer cells induce the overexpression of 
Figure 1. Drug mechanisms: drug interaction with palbociclib and ribociclib. If the drug is a prodrug, a CYP3A4 inhibitor will 
cause loss of efficacy and/or enhanced toxicity by the accumulated prodrug. The metabolism of palbociclib and ribociclib is 
described when they cross the hepatocyte membrane, mainly by passive diffusion, to be metabolized by the cytochrome P450 
pathway, specifically by the CYP3A4 isoenzyme. The blue arrows indicate how an inducer drug acts on CYP3A4 and accelerates the 
production of CYP3A4 substrate (palbociclib and ribociclib) and as a consequence decreases the concentration drug in the blood, 
leading to a loss of efficacy. The red arrows indicate how a CYP3A4 inhibiting drug (palbociclib and ribociclib) decreases CYP3A4’s 
metabolic capacity and therefore a lesser amount of substrate will be formed to be eliminated and the drug would accumulate in 
the blood giving rise to toxicity.
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this membrane efflux pump, facilitating a resis-
tance to anticancer agents.16 In addition, some 
drugs can modulate P-gp function, either by 
enhancing (such as most antiepileptics) or inhibit-
ing (such as verapamil or quinidine) its expres-
sion.18,19 When the membrane transporter is 
overexpressed, the drug substrate is carried out of 
the cells, for example, to the intestinal lumen, and 
consequently decreases its plasmatic concentra-
tion. By contrast, the inhibition of the efflux pump 
increases the plasmatic concentration of the drug 
substrate, with a subsequent enhanced risk of tox-
icity (Figure 2).
Membrane transporters are divided in two super-
families: ATP-binding cassette (ABC), composed 
of efflux pumps and solute carrier (SLC), com-
posed of uptake pumps.7
Available data from in vitro studies suggest that 
palbociclib passes through the membrane by pas-
sive diffusion, so it is not a substrate for mem-
brane transporters in most tissues.16 However, 
palbociclib is actively thrown out of the cell by 
P-gp and BCRP at the BBB level,20,21 which 
would explain its poor brain penetration com-
pared with an intact BBB. Ribociclib is a sub-
strate for intestinal P-gp22 and probably slightly 
less affected by BBB membrane transporters.23,24
Based on in vitro data, palbociclib is predicted to 
have the potential to inhibit intestinal P-gp, 
BCRP and organic cationic transporter (OCT)1, 
while ribociclib can potentially inhibit P-gp, 
BCRP, organic anion-transporting polypeptide 
(OATP)1B1, OATP1B3, OCT1, OCT2, bile 
salt export pump (BSEP) and multidrug and 
toxin extrusion protein (MATE)1 activities. 
Consequently, palbociclib and ribociclib may 
increase the side effects of drugs, which are sub-
strates for these transporters.
Palbociclib has a low potential to inhibit OATP1B1, 
OATP1B3, BSEP, OAT1, OAT3 and OCT2, so 
DDIs are not expected with the substrates for these 
transporters. Table S2 illustrates membrane trans-
porters, their localization and examples of drugs 
that are substrates for each transporter (Table S2, 
Supplementary material, File 1).
Take-home messages
 Ribociclib can be taken with or without 
food, and DDIs are not expected with PPIs. 
By contrast, palbociclib should be taken 
with food, and concomitant PPIs should be 
avoided.
 Both palbociclib and ribociclib are sub-
strates of the CYP3A4 enzymatic complex. 
As substrates for CYP3A4, the co-adminis-
tration of palbociclib or ribociclib with 
strong or moderate CYP3A4 inhibitors or 
inducers may increase or decrease the AUC 
of palbociclib or ribociclib, respectively, 
leading either to a risk of increased toxicity 
or decreased efficacy.
 Palbociclib is a weak inhibitor of CYP3A4, 
but a dose reduction of substrates with a 
NTI is suggested when taken concomi-
tantly with palbociclib. Ribociclib is a 
moderate inhibitor at a dose of 400 mg/day 
and a strong inhibitor at a dose of 600 mg/
day, so it may lead to increased serum 
Table 1. Dose modification of palbociclib or ribociclib in co-administration with drug inhibitors or inducers of CYP3A4.
Strong inhibitor Moderate 
inhibitor
Weak 
inhibitor
Strong inducer Moderate 
inducer
Weak 
inducer
Palbociclib
125 mg once 
a day, 3 
weeks on/ 1 
week off
Should be 
avoided. If 
unavoidable, 
reduce 
palbociclib dose 
to 75 mg.*
Risk of increased 
exposure.
Monitor for 
possible 
increased toxicity.
Low risk of 
increased 
exposure.
Should be avoided.
Consider using an 
alternative with less 
potential to induce 
CYP3A4.
Risk of 
decreased 
exposure and 
lack of efficacy.
Monitor.
Low risk of 
decreased 
exposure.
Ribociclib
600 mg once 
a day, 3 
weeks on/1 
week off
Should be 
avoided, if 
unavoidable, 
reduce ribociclib 
dose to 400 mg.*
Monitoring. Low risk of 
increased 
exposure.
Should be avoided.
Consider using an 
alternative with less 
potential to induce 
CYP3A4.
Risk of 
decreased 
exposure and 
lack of efficacy.
Monitor
Low risk of 
decreased 
exposure.
* The reduction must be maintained during the treatment with the inhibitor and at least five half-lives of elimination after its withdrawal. A half-life 
of elimination is defined as the time required to eliminate 50% of the drug from the organism.
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concentrations of CYP3A4 substrates in a 
more extensive way.
 Palbociclib has the potential to inhibit intes-
tinal P-gp, BCRP and OCT1, while riboci-
clib can potentially inhibit P-gp, BCRP, 
OATP1B1, OATP1B3, OCT1, OCT2, 
BSEP and MATE1 activities. Consequently, 
palbociclib and ribociclib may increase the 
side effects of drugs, which are substrates for 
these membrane transporters.
QTc for oncologists: how to evaluate and 
manage it
The evaluation of the QTc interval, despite its 
apparent simplicity, has been a controversial issue 
among health professionals, whether or not they 
are cardiologists. In addition, some studies evalu-
ating the consistency of its measurement between 
professionals are far from optimal. Less than 25% 
of nonexpert physicians seem able to correctly 
measure this interval.25
The QT, as its name denotes, is the interval between 
the beginning of the QRS complex and the end 
of the T wave on an electrocardiogram (ECG) 
(Figure 3), while QTc represents the QT corrected 
by the heart rate. The QT groups all the electrical 
activity of the ventricle, including depolarization 
and repolarization, and it basically represents an 
approach to the duration of the ventricular repolari-
zation process, which is a consequence of a positive 
charge efflux from the cells (Ito, Ica, IKs and IKr 
currents).
In spite of the simplicity of the concept, there 
usually are discrepancies regarding where to 
Figure 2. The membrane transporters on which palbociclib (OCT1, P-gp, BCRP) and ribociclib (P-gp, BCRP, 
OATP1B1, OATP1B3, OCT1, OCT2, BSEP, MATE1) can act are illustrated. According to an in vitro study, 
palbociclib and ribociclib act as inhibitors of these transporters. As a result, a greater amount of drugs that 
are substrates for these transporters would accumulate in the blood causing the appearance of adverse 
effects. Those coloured in green refer to the ABC superfamily efflux pumps. Those coloured in blue refer to the 
SLC superfamily, which uptake the drug in the enterocyte, hepatocyte, proximal tubule cell and neuron.
ABC, ATP-binding cassette; BBB, blood brain barrier; BCRP, breast cancer resistance protein; BSEP, bile salt export 
pump; MATE1, multidrug and toxin extrusion protein; OATP, organic anion-transporting polypeptide; OCT, organic cationic 
transporter; P-gp, P-glycoprotein; SLC, solute carrier.
Figure 3. QT interval.
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perform QT measurements. The main accepted 
strategy is to measure it on the ECG leads, where 
the waves are clearly seen. Often, due to the ori-
entation of the ventricular vectors, lead II is the 
best for this purpose. Other leads could be used, 
aVR, aVF, V5, V6 and V4, in this order. By con-
trast, aVL is considered the worst lead to quantify 
the QT interval.26
Another source of controversy is the location of QT 
limits. Often, the end of the T wave is not clear, 
especially in the presence of U waves. A pragmatic 
method to solve this issue is the so-called ‘tangent 
method’. It basically traces a tangent line following 
the descending part of the T wave and measures 
the interval up to the point where this line crosses 
the isoelectric line (Figure 4).26,27
Moreover, repolarization duration, and therefore 
QT, is heavily influenced by multiple variables, 
heart rate being one of the most relevant. In physi-
ological conditions, at increasing heart rates, the 
QT interval decreases due to shortening of the 
repolarization time (Figure 5). That is why we ulti-
mately take QTc as a reference measure and use 
mathematical methods to correct QT duration 
according to heart rate. The most widely used 
method among cardiologists, and the most recom-
mended for its simplicity and availability (e.g. 
apps, rules, etc.), is the Bazett formula (see 
Equation 1, Table S3, Supplementary material, 
File1). This method is far from optimal, since it 
‘overcorrects; at high heart rates and ‘undercor-
rects’ at low heart rates.28 Most cancer clinical tri-
als, however, require the Fridericia correction 
formula (see Equation 2, Table S3, Supplementary 
material, File1). Fridericia’s method, together with 
the Framingham correction (Equation 3, Table 
S3, Supplementary material, File1), showed in fact 
the best rate correction, and significantly improved 
a prediction of 30-day and 1-year mortality com-
pared with Bazett’s method in a recent study.29 
Bazett overestimated the number of patients with 
potentially dangerous QTc prolongation, which 
could lead to unnecessary safety measurements 
and withholding from the patient the first choice 
medication. There are online tools to calculate all 
three mentioned formulae.
QT and QTc are also influenced by QRS dura-
tion, as the QRS complex is actually included in 
the interval. For an abnormal QRS widening, a 
method should be used to correct (subtract) the 
contribution of this depolarization abnormality 
into the QTc value. The most widely used 
method, and the easiest approach, is to use the 
JT, that is, the interval between the J point (end of 
the QRS) and the end of the T wave. However, 
there are several complex mathematical methods 
that can be used to perform the correction.
So, why is QTc duration clinically important? The 
QTc interval is important because the prolonga-
tion of repolarization favours the development of 
polymorphic ventricular tachycardia or torsades de 
pointes (TdP) ECG, a condition associated with 
risk of arrhythmic death. Then, the physician’s 
efforts should be focused on identifying subjects 
with risk for developing this tragic event.
There are two main reasons why a QTc interval 
may be prolonged in a subject. The first one is an 
inherited condition, where at least one of the 
Figure 4. Tangent method to accurately measure the 
end of the T wave. Figure 5. Heart rate influence over QTc. In the upper 
panel, a normal duration of QTc is noted. In the lower 
panel, heart rate is increased, evidencing a long QTc 
(when corrected) that in absolute terms has a similar 
duration when compared with the upper one.
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mechanisms controlling the repolarization pro-
cess is abnormal. Several diseases sharing this 
type of abnormality are grouped under the name 
congenital long QT (LQT) syndrome. Hundreds 
of mutations in at least 12 genes have been associ-
ated with this condition. Most mutations are 
located in ion channels involved in the repolariza-
tion process. The three commonest subtypes 
(LQT1-3) involve genes KCNQ1, KCNH2 and 
SCN5A, respectively. The treatment and diagno-
sis of LQT syndrome are beyond the scope of this 
manuscript. The other reason why a QT interval 
can show an abnormal prolongation is the so-
called acquired LQT. Multiple factors can influ-
ence QT duration and produce an abnormal 
duration of the interval. One of the main factors is 
the use of drugs able to bind KCNH2 and, conse-
quently, cause an inhibition of the IKr current.30
In most cases, however, there is more than one fac-
tor influencing a drug-induced acquired QTc pro-
longation (e.g. ionic abnormalities, genetic 
background, etc.) and hence, the probability of 
developing TdP. Table 2 shows the factors that 
can increase this risk. Some are nonmodifiable 
variables, such as sex. The QTc interval is, on 
average, longer in women than in men so the QTc 
upper limit of normality for men is 450 ms and 460 
ms for women. Most of the other known risk fac-
tors are actionable or may be minimized. In fact, 
the first approach to treat acquired LQT is to cor-
rect these possible coexisting factors, to determine 
the risk of developing a major arrhythmic event in 
comparison with the benefit provided by the likely 
culprit drug and to evaluate clinically the presence 
of symptoms associated with QTc prolongation 
(syncope). In general, with a QTc over 480 ms, the 
suspicious drug should be withdrawn, unless its 
clinical benefit surpasses the potential risks for 
arrhythmia. If a QTc is over 500 ms, it is manda-
tory to withdraw all possible QTc-prolonging 
agents. Patients with baseline QTc prolongation, 
significant QTc prolongation (500 ms), associated 
symptoms (syncope) or the presence of other fac-
tors that increase the risk of TdP (Table 2), regard-
less of the quantity of QTc prolongation, should be 
carefully evaluated by a cardiologist.
Prevention is a key component in acquired LQT 
management, and implies an increased awareness 
among physicians regarding the potential of certain 
drugs to prolong QTc. Although the list of drugs 
with the potential for prolonging QTc interval 
increases daily, there are public resources available 
that can simplify their identification. The most 
widely used resource, which is also continuously 
updated, is the CredibleMeds database (https://
crediblemeds.org).31 According to their risk of TdP 
development, drugs are categorized as known risk 
(KR), possible risk (PR) and conditional risk (CR). 
Definitions for each category are illustrated in 
Table 3. The preventive approach also includes 
identifying, by means of a clinical interview, the risk 
of suffering a congenital long QT syndrome. A 
family history of premature sudden death, family 
history of congenital LQT or recurrent syncope 
should suspect this condition. This background or 
the evidence for an acquired LQT development 
should prompt an evaluation by the cardiologist.
Regarding CDK4/6i, and in spite of the fact that 
the risk of acquired LQT has been especially linked 
to ribociclib rather than palbociclib (see “Digging 
for neutropenia, QTc and infections: What actu-
ally matters?” section), the panel recommended 
the careful evaluation of all patients that will 
receive both palbociclib and ribociclib (baseline 
ECG and medical history) and avoid, if possible, 
concomitant QTc-prolonging drugs. Based on eli-
gibility criteria of the trials performed, palbociclib 
should be avoided in patients with baseline prolon-
gation greater than 480 ms, while ribociclib should 
be avoided with baseline QTc greater than 450 ms.
ECG controls should be especially performed in 
patients receiving ribociclib, and repeated at least 
Table 2. Factors related to TdP development.
Female sex
Bradycardia
Hypokalaemia
Heart failure
Ventricular hypertrophy
Recent cardioversion from atrial fibrillation
High concentration of the drug with known, 
possible or conditional risk of TdP
Baseline QTc prolongation
Rapid rate of infusion of QTc-prolonging drug
Subclinical long QTc syndrome
Ion channel polymorphisms
Severe hypomagnesaemia
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15 days after starting treatment during the first 
two cycles (see guidelines in “Digging for neutro-
penia, QTc and infections: What actually mat-
ters?” section). The panel also recommended 
repeating ECG in patients who started palboci-
clib with baseline grade 1 QTc (QTc between 
450 ms and 480 ms) at least 15 days after the 
initiation of treatment. In addition, the ECG 
should also be repeated when QTc prolongation 
is suspected (e.g. syncope) or new concurrent 
conditions or drugs make it more likely to cause 
an adverse effect. Furthermore, careful monitor-
ing should be performed in patients with risk of 
QTc prolongation (Table 3), including those 
affected with any diagnosed cardiac comorbidity.
Take-home messages
 QTc prolongation should be suspected 
even with normal QTc on baseline ECG in 
patients with a history of recurrent syncope 
or a family history of LQT syndrome or 
sudden death. These aspects should be 
incorporated into the oncologist clinical 
interview.
 Acquired QT prolongation, like the risk of 
TdP, is usually multifactorial. The correc-
tion of all contributing factors should 
always be taken into account.
 Patients receiving drugs with the potential 
for prolonging QTc should be carefully 
evaluated at baseline and followed up 
according to the pharmacology of the drug. 
To decrease the risk, it is key to avoid the 
concomitant use of more than one poten-
tially QTc-prolonging agent.
 Once acquired LQT syndrome is diagnosed, 
a careful risk assessment should be per-
formed, including clinical assessment, for 
the presence of associated symptoms (syn-
cope). In general, the suspicious agent must 
be withdrawn if the patient is symptomatic, 
if QTc is more than 500 ms, or if other risk 
factors for TdP coexist. If QTc is between 
480 ms and 500 ms, the suspected drug 
should be maintained only if the benefit sur-
passes the risk, and a cardiologist assessment 
and follow up are established.
Psychotropic drugs in the breast-cancer 
population: management of antidepressants in 
patients under CDK4/6i treatments
Prevalence of affective disorders in the breast-can-
cer population. MBC disease implies a serious 
threat to health and life. In addition to the psy-
chological stress, there is growing evidence that 
biological stress caused by both the tumour and 
the treatment could directly affect brain function 
and facilitate the appearance of cognitive and 
affective symptoms.32–35
The prevalence of depressive symptoms among 
survivors of breast cancer (up to 66%) appears to 
be significantly higher in comparison to the gen-
eral population, and persists longer (over 5 years) 
after diagnosis. By contrast, the prevalence of 
anxiety (up to 33%) does not seem to be signifi-
cantly higher.36
Sleep disorders are present in 65% of women survi-
vors of breast cancer versus 55% of a control group 
of the same age; its severity correlated with the 
presence of depressive symptoms, comorbidities, 
hot flashes and the residual effects of cancer.37
As for the metastatic disease (main focus of the 
present review), almost a quarter and a third of 
patients experience clinically relevant symptoms of 
depression and anxiety, respectively; both condi-
tions are reported to be more common in patients 
with MBC treated with CT than in those receiving 
ET.38 However, an enhanced risk of depression 
Table 3. Categories of drugs according to their risk of TdP: the Arizona Center for Education and Research on 
Therapeutics (AZCERT) classification.29
Category Definition
Known risk of TdP Drug causes frequent QTc prolongation. Risk of TdP is dose dependent.
Possible risk of TdP Drug frequently prolongs QTc, but TdP rarely ensues.
Conditional risk of TdP The risk of the drug causing QTc prolongation and TdP depends on the presence 
of essential cofactors such as hypokalaemia, promoting the adverse reaction 
(‘conditional’ risk).
TdP, torsade de pointes.
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has been noted in patients with MBC harbouring 
hormone-receptor positive (HR+) tumours; and 
for this HR+ population, a shorter median overall 
survival has been described in those women with 
depressive symptoms.39 Most importantly, in a 
prospective study including 125 patients with 
MBC, the improvement of depressive symptoms 
during the first year of intervention was associated 
with a subsequent longer survival.40
Treatment with antidepressants. Antidepressants 
are the drugs indicated for the treatment of 
depression, but they are also useful to treat anxi-
ety and stress-related disorders by basically mod-
ulating the monoaminergic neurotransmission.
The pharmacological treatment of depression 
started in mid-20th century with the discovery of 
tricyclic antidepressants (TCAs) and monoamine 
oxidase inhibitors (MAOIs). TCAs are mostly 
anticholinergic and have prominent side effects. 
MAOIs are also associated with a high risk of toxic-
ity, DDIs and food interactions. Hence, both drug 
groups should be avoided in oncological patients, 
with the exception of amitriptyline, which is useful 
at very low doses to alleviate neuropathic pain.
Nowadays, new generations of antidepressants 
are available. They are equally effective, safer and 
better tolerated. Table S4 categorizes all these 
drugs according to their mechanism of action41 
(Table S4, Supplementary material, File 1).
How to choose the right antidepressant. Selec-
tive serotonin reuptake inhibitors (SSRIs) repre-
sent the first-line pharmacological treatment for a 
depressive disorder, but other antidepressants can 
be chosen according to the accompanying symp-
toms (e.g. inhibition, anxiety, agitation, insomnia, 
anorexia etc.).
Aside from depression, antidepressants may be 
indicated to treat specific symptoms such as 
insomnia (mirtazapine and trazodone), neuro-
pathic pain (duloxetine and amitriptyline), hot 
flashes (venlafaxine and SSRIs), lack of appetite, 
nausea and/or vomiting (mirtazapine) and fatigue 
(bupropion and methylphenidate).41
Side effects and QTc prolongation. Second-
generation antidepressants, albeit safe overall, 
may cause untoward effects such as hypersen-
sitivity reactions, hepatotoxicity, gastrointesti-
nal, cardiovascular or genitourinary symptoms, 
hyponatraemia, metabolic disorders or increased 
risk of bleeding; it is worth mentioning the risk 
of seizures related to bupropion, as well as the 
occurrence of withdrawal symptoms upon treat-
ment discontinuation, most prominent with ven-
lafaxine and paroxetine.42
A major concern is the effect of antidepressants on 
QTc-interval prolongation and the risk of TdP 
(see “QTc for oncologists: How to evaluate and 
manage it” section). Citalopram and escitalopram 
prolong QTc and have known risk of TdP (“QTc 
for oncologists: How to evaluate and manage it” 
section) at therapeutic doses, although the concern 
created by this issue has been a matter of debate,43,44 
they are not recommended. Mirtazapine and ven-
lafaxine are drugs with possible risk for TdP and 
must be administered with great caution with con-
current medical pathologies and polypharmacy. 
Other SSRIs, such as fluvoxamine, fluoxetine, par-
oxetine and sertraline, have been associated with a 
modest increase in the QTc interval,45 and have a 
conditional risk for TdP; they are the best option, 
provided that the conditions for their administra-
tion are taken into account (i.e. electrolyte imbal-
ance, hyper- or hypothyroidism or concomitant 
use of QTc-prolonging drugs). At the moment, 
there is no evidence of TdP risk for duloxetine, 
desvenlafaxine, bupropion or for the newer antide-
pressants, vortioxetine and vilazodone.
DDIs with CDK4/6i. Antidepressants may pre-
sent pharmacodynamic and pharmacokinetic 
interactions.
CDK4/6i palbociclib and ribociclib have been 
associated with QTc prolongation,46 so the con-
current use of antidepressants with TdP KR and 
PR should be avoided; antidepressants with TdP 
CR can be administered, provided that appropri-
ate monitoring and control of other risk factors 
for TdP are established.
Palbociclib and ribociclib are metabolized 
mainly by CYP3A4, therefore, antidepressants 
with an inhibitory effect on CYP3A4 (i.e. nefazo-
done, currently not available in Spain, and flu-
voxamine) should be avoided (see also “Drug 
metabolic pathways and membrane transport-
ers: How to interpret drug-drug interactions 
with palbociclib and ribociclib?” section and col-
laborative module).
Ribociclib, as an inhibitor of CYP3A4,47 may 
increase the levels of antidepressants metabolized 
by CYP3A4, such as trazodone, mirtazapine, 
venlafaxine, reboxetine and vilazodone. Ribociclib 
is also an inhibitor of CYP1A2 and could affect 
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the levels of amitriptyline, fluvoxamine, duloxe-
tine and mirtazapine, but to a lesser extent.
Take-home messages
 Depressive, sleeping and anxiety disorders 
are very common in patients with MBC and 
should be promptly recognized and treated. 
Published data suggest a worse overall sur-
vival for patients with luminal MBC suffer-
ing depression; importantly, an improvement 
in long-term outcomes has been observed 
for those patients with MBC experiencing a 
reduction of their depressive symptoms. 
DDIs with palbociclib or ribociclib exist for 
most antidepressants, either via CYP3A4 or 
mostly via QTc prolongation.
Digging for neutropaenia, QTc and infections: 
what actually matters?
For most oncologists, both palbociclib and riboci-
clib are considered to be well tolerated and very 
similar drugs in terms of clinical efficacy. However, 
slight differences in their side-effect profiles have 
been described. The aim of this section is to review 
these similarities and differences in detail, with the 
focus on three clinically relevant side effects, that 
is, neutropaenia, drug-induced QTc prolongation 
and infections. For this purpose, data have been 
compiled from multiple sources. Reports from the 
PALOMA and MONALEESA trials4–6,48,49 and 
data from conference abstracts, the ClinicalTrials.
gov website, European Medicines Agency (EMA) 
evaluations50,51 and the Summary of Product 
Characteristics (SPC) of both drugs were compre-
hensively reviewed. At the time of the workshop, 
data from the most recent trial, MONALEESA-3, 
was only known from an abstract, but the com-
plete results were released immediately after-
wards,52 and therefore are also included here, 
together with the preliminary results of the 
CompLEEment study.50
Neutropaenia. The results from the PALOMA-2 
trial showed that neutropaenia is the most com-
mon haematological (and nonhaematological) 
side effect associated with palbociclib. In that trial, 
all-grade neutropaenia and grade (G) 3 and 4 
neutropaenia appeared in more than 80% and 
almost 70% of patients, respectively.3 About 20% 
of women experienced between three and five epi-
sodes of neutropaenia during treatment, and an 
additional 17% had more than six episodes.48 
Median time from first dose to first onset of neu-
tropaenia of any grade was 13 days, and median 
duration of G3/G4 neutropaenia was 15 days and 
9 days, respectively.51 Due to this fact, almost 80% 
of patients needed temporary discontinuation of 
palbociclib, and in 33%, a dose reduction.3 Some 
differences between geographical areas were sug-
gested.48 Nonetheless, it must be emphasized that 
only 1.5% incidence of febrile neutropaenia was 
observed, and just 1.5% of patients discontinued 
palbociclib due to neutropaenia.3 Similar results 
were observed in the PALOMA-3 trial in patients 
that experienced neutropaenic fever, and the rate 
of discontinuation due to neutropaenia was 2%.51 
The recommendations of the palbociclib last data 
sheet included a close follow up of the G3 neutro-
paenia onset and duration during the first two 
cycles, and a dose reduction if G3/G4 neutropae-
nia is frequent or represents repetitive delays in 
day 1 of subsequent cycles. The majority of neu-
tropaenia episodes were not complicated.6 Impor-
tantly and according to cumulative data from the 
PALOMA trials,3,6,48,53–55 most patients with neu-
tropaenia will not have concomitant infections.
Ribociclib shows a similar incidence of G3/G4 neu-
tropaenia (62%).5 However, by indirect compari-
son with the PALOMA trials, a lower incidence of 
neutropaenia episodes, dose interruption (50% in 
the first year, 18% afterwards) and incidence of 
G3/G4 neutropaenia beyond 6 months have been 
reported with ribociclib in pivotal trials.4,5,56,57 This 
is probably due to the restrictive G3 neutropaenia 
management in the MONALEESA-2 trial, also 
implemented in the SPC, which required a dose 
reduction of ribociclib in the presence of a second 
episode of G3 neutropaenia. Overall, 54% of 
women had a dose reduction of ribociclib (mostly 
just one) and this was mainly due to neutropaenia 
(24% of all patients in the ribociclib arm).50 
Interruptions due to neutropaenia were reported in 
42% of patients.5 Median time from first dose to 
first onset of neutropaenia of any grade was 16 days 
(29 days for G3/G4) and median duration of ⩾ G3 
neutropaenia was 15 days.50 Median time to first 
dose reduction was 2.9 months.50 The rate of per-
manent ribociclib discontinuation was 0.9%.50 
Again, most patients did not experience concomi-
tant infections, and the incidence of febrile neutro-
paenia was very low (1.2%).4 Data from the 
MONALEESA-749 and MONALEESA-3 trials52 
confirmed a similar incidence of G3/G4 neutropae-
nia (Table S5, Supplementary material, File 1) 
with low rates of febrile neutropaenia (1–2%).
Drug-induced QTc prolongation. A review of the 
QTc clinical significance and evaluation has been 
performed in “QTc for oncologists: How to eval-
uate and manage it” section, with a focus on the 
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reported incidence of QTc with palbociclib and 
ribociclib.
Evaluation of QTc prolongation differed between 
palbociclib and ribociclib trials (Table 4). 
Palbociclib had been associated with QTc prolon-
gation in dogs, but not in phase I trials.58 
Therefore, the PALOMA trials permitted the 
inclusion of patients with basal QTc < 480 ms. By 
contrast, asymptomatic QTc prolongation was 
observed in phase I trials with ribociclib at doses 
⩾ 600 mg.59 Therefore, closer monitoring and 
more strict inclusion criteria were established in 
the MONALEESA trials. All patients with basal 
QTc > 450 ms were excluded, and all ECGs were 
electronically reported and centrally evaluated.
Regarding palbociclib, a substudy aimed at evaluat-
ing QTc prolongation was performed in the context 
of the PALOMA-2 trial.62 ECG on day 0 and on 
C1D14 was centrally evaluated in 123 of the 660 
patients included in the main study. No associations 
between palbociclib and prolongation of QTc were 
found. Both the EMA evaluation and the SPC of 
palbociclib described this absence of correlation. 
However, data from all 660 patients evaluated 
locally by the investigators showed an incidence of 
G2/G3 QTc prolongation (Fridericia correction) of 
Table 4. QTc evaluation and results in the PALOMA-2 and MONALEESA-2 trials.4,5,60,61
Participants Evaluation Timing Results
PALOMA-260,61 Substudy ECG (n = 123)
Basal QTc < 481 ms.
Preferable 
automatic ECG 
lecture.
Triplicate ECG.
Centrally manual 
evaluation.
Day 0:
preD, 2, 4, 6 
and 8 h later.
C1D14:
preD, 2, 4, 6 
and 8 h later.
No patients had a postbaseline 
absolute maximum QTc ⩾ 500 ms or a 
ΔQTc ⩾ 60 ms during the intensive QTc 
assessment period.
Correlation between QTc and 
palbociclib concentration was weak.
Aromatase inhibitors the upper bounds 
of one-sided 95% confidence interval 
of ΔQTc for all five QTc postbaseline 
time points were less than 20 ms, 
the postbaseline QTcs’ were to be 
considered noninferior to baseline 
and no clinically relevant effects of 
palbociclib in QTc were concluded
All population (n = 666)
Basal QTc < 481 ms
Preferable 
automatic ECG 
lecture.
Triplicate ECG.
Centrally manual 
evaluation.
Day 0:
C1D1, preD
C1D14, preD
C2D14, preD
C4D1, preD
C7D1, preD
C10D1, preD
QTc prolongation G2:
palbociclib: 1.6%, placebo 0.9%.
QTc prolongation G3:
palbociclib: 0.2%, placebo 0%*.
MONALEESA-24,5 All population (n = 668)
Basal QTc < 451 ms
Locally automatic 
ECG lecture.
Triplicate ECG.
Centrally manual 
evaluation.
Day 0:
C1D1, preD
C1D14, preD
C1D14, postD
C2D1, preD
C2D1, postD
C3D1, preD
C3D1, postD
C4D1, preD
C5D1, preD
C6D1, preD
C6D1, postD
C7D1, preD
C8D1, preD
C9D1, preD
C9D1, postD
QTc prolongation G2:
ribociclib: 3.6%, placebo 0.6%.
QTc prolongation G3:
palbociclib: 0.6%, placebo 0%.$
*p values not provided.
$Statistically significant differences for both G2 and G3 QTc prolongation.
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1.6% and 0.2% in the palbociclib arm versus 0.9% 
and 0% in the placebo arm, respectively.63
In the MONALEESA-2 trial, an increase in the 
incidence of QTc prolongation in the ribociclib 
arm compared with the placebo arm was described. 
The incidence of G2 and G3 prolongation was 
3.6% and 0.6%, respectively, with ribociclib versus 
0.6% and 0% with placebo. QTcF (Fredericia’s 
correction formula)-related AEs occurred within 
30 days of initiation of treatment. Among the 
patients who had QTcF prolongation of > 480 
ms, the median time to onset was 15 days and 
these changes were reversible with dose interrup-
tion and/or dose reduction. There were no reports 
of QTc prolongation after 18 months of treat-
ment. There was one death in the ribociclib arm, 
which was attributed to G2 QTc prolongation; 
other risk factors for QTc prolongation were 
detected in this patient, such as G3 hypokalaemia 
and concomitant use of a prohibited drug with a 
known risk for QTc prolongation.4,5,51 Both the 
EMA evaluation and ribociclib SPC indicate 
that an ECG should be performed before initiat-
ing treatment and repeated at approximately 
C1D14 and C2D1, then as clinically indicated. 
Appropriate monitoring of serum electrolytes 
should be performed before the start of ribociclib 
treatment and at the beginning of each of the first 
six cycles. The use of ribociclib should be avoided 
in patients who already have, or who are, at sig-
nificant risk of developing QTc prolongation. The 
concomitant use of drugs with risk of QTc prolon-
gation should be checked at any time, including 
the use of medicinal or herbal products.64
In the more recently published MONALEESA-7 
and MONALEESA-3 trials, the incidence of 
reported QTc prolongation (⩾ G2) was 7% and 
3.9%, respectively. Grade 3 QTc prolongation 
was observed in 1% of MONALEESA-7 patients 
and 1.7% in the MONALEESA-3 population 
(0.4% in the placebo arm). Corresponding rates 
in their placebo arms are summarized in Table 5. 
The highest rate of G2 QTc in MONALEESA-7 
may be due to the concomitant administration of 
tamoxifen, a drug with a well-known risk of QTcF 
potential prolongation: in the ribociclib group of 
the study, an increase of more than 60 ms from 
baseline in the QTcF interval was observed in 
16% of patients receiving tamoxifen versus 7% 
receiving an NSAID (Nonsteroidal anti-inflam-
matory drug); in the placebo group this increase 
was observed in 7% of patients receiving tamoxifen 
versus 0% in patients receiving an NSAID. As for 
the last main study conducted, the CompLEEment 
phase IIIb trial, a low incidence of QTcF prolon-
gation ⩾ 3 (0.5%) has been preliminarily observed 
among the 1008 patients analysed.65 This lower 
incidence in comparison with prior ribociclib tri-
als might be due to an enhanced awareness of this 
toxicity among the investigators, leading to a bet-
ter management of concomitant risk factors for 
QTc prolongation. However, this interpretation 
is flawed by the short follow up in this study and 
the lack of a control arm. Overall, the incidence of 
discontinuation due to QTc prolongation with 
ribociclib was less than 1% in all ribociclib trials.
Take-home messages
 Ribociclib has been associated with a 
higher incidence of G2/G3 QTc prolonga-
tion compared with placebo (3.6–6%/0.5–
1.7% versus 0.6–1.7%/< 1%). A slightly 
increased incidence of QTc prolongation 
was seen in the palbociclib arm of the 
PALOMA-2 trial compared with the pla-
cebo arm (1.6%/0.2% versus 0.9/0%), 
which was not observed in a centrally 
reviewed PALOMA-2 substudy with ECGs 
Table 5. Incidences of QTc prolongation in main ribociclib trials.
QTc prolongation
MONALEESA-25 G2: ribociclib 3.6% versus placebo 0.6%$
G3: ribociclib 0.6% versus placebo 0%$
MONALEESA-352 ⩾ 2 : ribociclib: 5.6% versus placebo: 2.5%*
MONALEESA-749 G2 : ribociclib 6% versus placebo 1%*
G3: ribociclib 1% versus placebo < 1%*
CompLEEment-165 G2: ribociclib: not recorded
G3: ribociclib: 0.5%
*p values not provided.
$Statistically significant differences for both G2 and G3 QTc prolongation.
Therapeutic Advances in Medical Oncology 11
14 journals.sagepub.com/home/tam
(at baseline and day 14). This toxicity 
appears early after treatment initiation and 
reverses after drug interruption. The panel 
also found it reasonable to follow a con-
servative approach with palbociclib and 
recommended a basal ECG before treat-
ment initiation with both CDK4/6i. Based 
on clinical trials eligibility criteria, riboci-
clib should not be started in patients with 
basal QTc > 450 ms and palbociclib with a 
QTc > 480 ms. Postbaseline QTc must be 
performed with ribociclib at C1D14 and 
C2D1, and then as clinically indicated, and 
whenever other risk factors are added (e.g. 
drugs with potential risk of QTc prolonga-
tion). The correction of all modifiable fac-
tors that can increase QTc (e.g. electrolyte 
imbalances) should be taken into account 
at any time during ribociclib treatment.
Infections. Overall, the introduction of CDK4/6i 
in breast-cancer trials has not been associated 
with a worryingly enhanced risk of infections. 
Overall, the combination of either palbociclib or 
ribociclib with ET was associated with only a 
slight increase of all-grade and G3/G4 infections 
with regard to ET alone. Most common infec-
tions with palbociclib in the PALOMA-2 trial 
were upper and lower respiratory tract infections 
(14% and 13%, respectively) and urinary infec-
tions (12% all grades), almost all G1 or G2. With 
ribociclib, in the MONALEESA-2 trial,5 the 
most frequent infectious conditions were upper 
respiratory tract infections, urinary tract infec-
tions and viral infections. Table S6 illustrates the 
incidence and grade of reported infections in piv-
otal trials with palbociclib and ribociclib (Table 
S6, Supplementary material, File 1).
Take-home messages
 Palbociclib and ribociclib show a similar inci-
dence and pattern of haematological toxicity, 
with more than 60% of patients experiencing 
G3/G4 neutropaenia. A slightly fewer num-
ber of neutropaenic episodes and dose inter-
ruptions over 6 months appear to occur with 
ribociclib by indirect comparison with palbo-
ciclib data. This may be related to the differ-
ent management of G3 neutropaenia, 
including early ribociclib dose reduction.
 A minor increase in most commonG1/G2 
infections with ribociclib and palbociclib is 
observed compared with placebo, which 
does not raise a major concern.
 Rates of febrile neutropaenia are below 2% 
in all studies.
Reflecting on liver toxicity: incidence and 
management. Who is at risk?
For the workshop, a comprehensive review of 
liver enzyme abnormalities during treatment with 
ribociclib and palbociclib was performed. As in 
“Digging for neutropenia, QTc and infections: 
What actually matters?” section, the results from 
the main published studies,3–6,48,49,52,53,55–57,65–67 
together with data available at clinicaltrials.gov, 
FDA/EMA documents and Pfizer/Novartis 
reports were considered.50,51,68–72 The US 
National Institutes of Health LiverTox database 
was also taken into account.70 Finally, a general 
PubMed/Google Scholar search was performed, 
including the terms <palbociclib>, <riboci-
clib>, <transaminitis>, <liver toxicity> and/or 
<liver failure>.
Ribociclib. Liver toxicity was not observed in 
phase 1 trials with ribociclib,59,73,74 but was 
closely monitored and strictly managed in phase 
III studies. Following the European Public 
Assessment Report, the management of transa-
minitis/liver toxicity during ribociclib treatment 
is summarized in Table 6, and mainly distin-
guishes aspartate aminotransferase (AST) and/
or alanine aminotransferase (ALT) with or with-
out concomitant elevation of bilirubin, the latter 
being the most clinically relevant.50 The fre-
quency of all-grade AST and/or ALT toxicity 
was higher in the ribociclib arms than in the pla-
cebo arms in all MONALEESA trials, and 
ranged between 15% and 20% (see also Table 
S7, Supplementary material, File 1 for G3/G4 
AEs).5,49,50,52 Liver toxicity was not described in 
the preliminary report of the CompLEEment 
trial, but the cut off for listing toxicities was 
above 15%.65 Rates of discontinuation due to 
liver toxicity (compared with the control arm) 
have been reported for the MONALEESA-2 and 
-7 trials, being very low in both studies (3% ver-
sus 0.6% in MONALEESA-2 and 3% versus 
1.2% in MONALEESA-7).
Abnormalities in liver function tests (LFTs) asso-
ciated with ribociclib were best characterized in 
the MONALEESA-2 trial. Here, G3/G4 liver tox-
icity was observed in 10.7% of women (37/344 
patients). The different patterns of liver toxicity 
observed and their management were reviewed by 
the FDA and are summarized in Table S8 (Table 
S8, Supplementary material, File 1).72 The most 
frequent LFT abnormalities were transaminitis, 
accounting for 54% (28/37) of all G3/G4 toxici-
ties. In addition, four patients had concomitant 
bilirubin elevation and met Hy’s law biochemical 
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criteria, three of which related to ribociclib. 
Overall, only five liver abnormalities were reported 
as serious adverse events (SAEs). LFTs recovered 
to normal levels in all patients within 154 days 
after ribociclib discontinuation.50,65 No deaths 
attributable to liver toxicity were observed. 
Around 84% (31/37) of G3/G4 ALT/AST eleva-
tion events occurred within the first 6 months 
after treatment initiation. Median time to onset of 
this toxicity was 57 days, and median time to reso-
lution (to normalization or grade ⩽ 2) was 24 
days.50,65 No cases meeting Hy’s law criteria were 
reported in the MONALEESA-7 trial.68 Overall, 
taking into account all the population receiving 
ribociclib in pivotal trials, G3 liver toxicity rates 
appear to be relatively low, ranging between 5% 
and 10%. Moreover, only 1% of patients experi-
enced life-threatening liver toxicity, and all liver 
abnormalities were reversible after ribociclib 
interruption.67,68 However, this toxicity raises 
a concern regarding the possibility of continuing 
ribociclib treatment, in particular because 
recovery may be slow and toxicity occurs early 
after treatment initiation. Since all studies required 
definitive drug discontinuation if recovery did not 
occur within 28 days of ribociclib interruption, 
most trial patients did not re-start ribociclib and, 
as a consequence, little evidence exists regarding 
the outcome of this strategy. Moreover, results 
from the few trial patients re-starting ribociclib 
because of faster liver enzyme recovery are proba-
bly not entirely applicable to other patients with 
later recoveries and who may re-start ribociclib 
outside the clinical trial setting.
Palbociclib. Overall, LFT abnormalities were not 
reported as AEs in the main palbociclib studies, 
but only those toxicities with frequencies above 
5% or 10% were included.3,6,48,53,55,66 Nonethe-
less, comprehensive data regarding all toxicities, 
independently of their frequency, are available at 
clinicaltrial.gov. According to this database, no 
liver toxicity was observed in the phase I trial 
with palbociclib and letrozole.71 In the phase II 
Table 6. Liver toxicity management with ribociclib according to EPAR.50 Main management differences 
compared with the MONALEESA-2 trial are presented in the footnote (a,b).
Grade 1*
(> ULN – 3 
× ULN)
Grade 2*
(> 3–5 × ULN)
Grade 3*
(> 5–20 × ULN)
Grade 4*
(> 20 × ULN)
AST and/or ALT 
elevations from 
baseline**, without 
increase in total 
bilirubin above  
2 × ULN
No dose 
adjustment 
is required.
Baseline grade < 2:
dose interruption until 
recovery to ⩽ baseline 
grade: resume ribociclib 
at the same dose level. If 
grade 2 recurs, resume 
ribociclib at next lower 
dose level.
Dose interruption 
of ribociclib until 
recovery to ⩽ 
baseline grade, 
then resume at next 
lower dose level.
If grade 3 recurs, 
discontinue 
ribociclib.
Discontinue 
ribociclib.
Baseline grade = 2:
no dose interruption.
Combined AST and/
or ALT elevations with 
total bilirubin increase 
in the absence of 
cholestasis
If patients develop ALT and/or AST > 3 × ULN together with total bilirubin
> 2 × ULN, irrespective of baseline grade, discontinue ribociclib.
*Grading according to Common Terminology Criteria for Adverse Events version 4.03
**Baseline = prior to treatment initiation.
LFTs should be performed before initiating treatment with ribociclib. After initiating treatment, LFTs should be performed 
every 2 weeks during the first two cycles, at the beginning of each of the subsequent four cycles, and then as clinically 
indicated. If grade ⩾ 2 abnormalities are noted, more frequent monitoring is recommended.This guideline follows the 
management indicated in the MONALEESA trials with two exceptions:
(a) no frequency for LFT monitoring is indicated after the re-introduction of ribociclib, when the drug was discontinued 
due to liver toxicity; by contrast, the MONALEESA-2 trial required LFTs to be performed twice a week for 2 weeks after 
resuming ribociclib; (b) there is no limited time period for liver toxicity recovery, beyond which it is not possible to re-start 
ribociclib; by contrast, all ribociclib trials limited that period to 28 days, after which ribociclib re-introductions were not 
allowed.
AST, aspartate aminotransferase; ALT, alanine aminotransferase; LFT, liver function test; ULN, upper limit of normal.
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randomized trial PALOMA-1, 7% and 1.20% of 
patients in the palbociclib arm who showed 
increases in AST and/or ALT experienced AEs 
and SAEs, respectively. These frequencies were 
slightly higher than in the control arm. Table S9 
in Supplementary material, File 1 illustrates the 
frequency of LFT abnormalities in the PALOMA 
trials 1, 2 and 3, and in a recently published 
pooled analysis.75 Overall, G3/G4 AST and/or 
ALT elevation rates ranged between 1.2% and 
3% with palbociclib versus 0 and 1% with pla-
cebo. No cases meeting Hy’s law criteria were 
observed in palbociclib-treated patients in all 
three PALOMA trials.75 The rate of discontinua-
tion for liver toxicity was 0.2% versus 0.1% with 
palbociclib versus placebo in the PALOMA-2 
trial and, to the authors’ knowledge, it has not 
been reported in the PALOMA-3 study. Regard-
ing the management of LFT abnormalities with 
palbociclib, no specific recommendations for 
nonhaematological toxicities were made in phase 
III trials, nor has it been established by regula-
tory agencies. Due to the low frequency of clini-
cally relevant liver toxicities with palbociclib, 
there is no mention of LFT monitoring by the 
FDA or in the EMA SPC.
Outside the clinical trial setting, two cases of 
pseudocirrhosis after treatment with palbociclib 
+ letrozole have been recently communicated.76 
The cases involved a 41-year-old Afro-American 
woman without prior liver disease and a 61-year-
old White woman with possible prior pseudocir-
rhosis. Both patients experienced fatigue and 
ascites, and their LFTs showed a cholestatic pat-
tern. The condition started after 3 months and 2 
months of palbociclib + letrozole initiation, 
respectively, and uniformly resulted in liver fail-
ure and death. Causality was attributed to pal-
bociclib, as no cases of pseudocirrhosis with 
letrozole had been previously reported. Drug-
induced pseudocirrhosis is an entity nowadays 
increasingly recognized in patients with breast 
cancer receiving several antineoplastic drugs, 
including capecitabine, gemcitabine, trastu-
zumab and paclitaxel; furthermore, it is often 
associated with rapid regression of extensive 
liver metastases.77–79 In these two cases, no infor-
mation regarding an objective response in the 
liver (if involved) was given, but the higher rate 
of objective responses described with the ET + 
CDK4/6i combination makes it reasonable for 
both cases to have a similar etiopathogenesis and 
points to the possibility of facing new cases in 
the future with any CDK4/6i.
Risk factors for CDK4/6i-related liver toxicity. No 
data regarding baseline characteristics of patients 
developing liver toxicity have been published. 
The incidence of transaminitis appears to be 
slightly inferior in the MONALEESA-7 trial 
(median age: 43 years)80 than in the MONA-
LEESA-2 and -3 trials (median age: 61 years and 
63 years, respectively), suggesting that an older 
age has a minor, if any, role in liver toxicity. All 
pivotal studies with palbociclib or ribociclib had 
an acceptable liver function as eligibility criteria. 
However, a screening for hepatitis virus B (HBV) 
or hepatitis virus C was not mandatory and, 
therefore, no data are available regarding liver 
toxicity in these patients.
At the workshop, the pre-existence of nonalco-
holic fatty liver disease in some patients who 
afterwards developed liver toxicity was discussed. 
A review of the literature revealed that the role of 
nonalcoholic fatty liver disease as a risk factor 
for drug-induced hepatotoxicity is a matter of 
debate.81,82 The main argument against the puta-
tive role of fatty liver in drug-induced liver injury 
is the different incidences of both entities, the for-
mer being a common condition and the latter a 
highly infrequent event.82 However, according to 
a recent publication,83 patients with nonalcoholic 
fatty liver disease and obesity certainly have an 
increased risk of drug-induced liver injury. More 
data about predictive factors of CDK4/6i-related 
liver toxicity, if any, are required. In the mean-
time, it seems reasonable to monitor closely LFTs 
in obese women with fatty liver disease receiving 
CDK4/6i, and, more particularly, ribociclib.
Take-home messages
 Ribociclib has been associated with an inci-
dence of G3 liver toxicity ranging between 
5% and 10%, so monitoring of liver func-
tion is required. Most liver abnormalities 
associated with ribociclib appear in the first 
6 months of treatment and constitute iso-
lated transaminitis, which reverts after 
treatment interruption. No deaths due to 
liver toxicity have been described in clinical 
trials and only 1.5% of patients (5/334) 
experienced concomitant rise in bilirubin 
levels and/or liver toxicity considered to be 
life threatening.
 Due to slow recovery of liver function after 
interruption for liver toxicity, most women 
did not re-start treatment in the context of 
clinical trials, therefore, few data exist regard-
ing the evolution of LFTs after ribociclib 
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re-introduction. No factors predictive of liver 
toxicity with ribociclib have been identified 
so far, although some reports have suggested 
nonalcohol fatty liver combined with obesity 
is a potential risk factor for drug-induced 
liver toxicity.
 Palbociclib is associated with very low rates 
of G3 transaminitis (1.2–3% with palboci-
clib versus 0–1% with placebo in randomized 
trials), with no cases meeting Hy’s law crite-
ria reported in all three PALOMA studies. 
Based on these data, no specific monitoring 
of liver function is recommended.
 Similarly to other antineoplastic drugs (e.g. 
capecitabine, trastuzumab and taxanes) 
able to induce rapid regression of extensive 
liver metastases, drug-induced pseudocir-
rhosis with CDK4/6i is also possible. Two 
cases with fatal outcomes related to palbo-
ciclib have been reported so far.
Revealing other toxicities: keeping alopecia in 
mind
The workshop also aimed to address other 
CDK4/6i toxicities for which specific manage-
ment exists. Table 7 summarizes the incidence of 
these other AEs in pivotal studies according to the 
clinicaltrials.gov database.60,63,84 After a pre-work 
showing that for almost all these toxicities there 
was neither specific management nor new data 
regarding management, so no further mention 
was made at the meeting. By contrast, recent data 
regarding the management of endocrine-induced 
alopecia was published and therefore this issue 
was particularly addressed.
For decades, endocrine-related alopecia has elic-
ited less interest than CT-induced alopecia, being 
frequently underreported in clinical trials. In a 
meta-analysis published in 2013, which included 
almost 20,000 patients with cancer from 35 stud-
ies, only 4.4% (95% confidence interval: 3.3–
5.9%) of endocrine-related alopecia was described 
on average, being more frequent with tamoxifen 
and with combinations of Luteinizing hormone-
releasing hormone (LHRH) analogues and 
tamoxifen/aromatase inhibitors.85 Recent com-
munications, however, described a substantially 
higher frequency of this entity.86,87 In a survey-
based study comprising 851 women with early 
breast cancer receiving AIs, 34% reported hair 
loss or hair thinning during their last month of 
therapy, hair changes that were not related to pre-
vious CT or age.88 Moreover, the frequency of 
endocrine-related alopecia appeared to increase 
with duration of treatment.86,87
Notably, a recent retrospective study aimed at 
characterizing endocrine-related alopecia in 
patients with breast cancer has been recently pub-
lished.87 The study included 112 patients with early 
disease treated with AIs and tamoxifen with/with-
out leuprolide. The severity of alopecia was grade 1 
in 93% of patients, and the pattern was similar to 
androgenetic alopecia thought to be the result of 
unsynchronized miniaturization of hair follicles. 
Mean time to onset of hair loss from ET initiation 
was 16.8 months (range: 1–91 months). A total of 
65 patients (58%) reported alopecia within the first 
12 months of ET. A total of 52 women answered a 
specific quality-of-life questionnaire (Hairdex ques-
tionnaire) exploring functioning, symptoms, stig-
matization, emotions and self-confidence. The 
questionnaire revealed that hair loss had the highest 
impact in the latter two domains. Importantly, 46 
of the 112 patients were treated with topical minox-
idil 5%, and 37 (80%) experienced a moderate or 
significant clinical improvement, as assessed by the 
investigator and a blinded reviewer. No AEs related 
to topical minoxidil were observed.
In palbociclib and ribociclib trials, all-grade alope-
cia was described in about one-third of patients in 
first-line trials,60,63 and in one out of six women in 
the second-third-line PALOMA-3 trial. These 
numbers are two or three-fold higher than alopecia 
rates observed with Et alone in the corresponding 
control arms (see Table 7). No studies addressing 
the characterization of alopecia related to CDK4/6i 
and ET have been published. The higher frequency 
of hair loss compared with ET alone may be related 
to the longer duration of the accompanying ET due 
to the improved progression-free survival with the 
combination, to a direct effect of CDK4/6i on the 
hair follicles by acting synergistically with ET toxic-
ity, or probably to both. Of note, all-grade alopecia 
has been reported with abemaciclib in monother-
apy in 9% of women (12/132 patients),89 suggest-
ing that the CDK4/6i themselves may provoke hair 
loss. No data exist on the efficacy of topical minoxi-
dil on patients treated with CDK4/6i. However, the 
mechanisms of action of minoxidil, albeit multiple, 
did not include any hormonal effect and seem to be 
basically related to its vasodilator properties on the 
scalp. Although systemic absorption has been 
reported,90 no DDIs were described after two dec-
ades of use, and only patients with heart disease are 
recommended to use with caution.91 Taking into 
account all data and the impact that hair loss has on 
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patients’ quality of life, the panel agreed that it was 
reasonable to prescribe topical minoxidil 5% in 
patients treated with CDK4/6i. This consideration 
did not apply to alpha-reductase inhibitors, such as 
finasteride or dutasteride. These drugs, by blocking 
conversion of testosterone to dihydrotestosterone, 
increase testosterone levels, with the subsequent 
risk of also increasing oestrogen levels after conver-
sion by the aromatase enzyme.
Take-home messages
 There is no specific management for other 
toxicities reported with palbociclib or riboci-
clib, such as stomatitis, nausea/vomiting, 
rash, increased lacrimation, dysgeusia, diar-
rhoea, etc., with the exception of avoiding 
DDIs when treatment for these toxicities are 
needed. Alopecia is a frequent event with 
CDK4/6i treatment due to prolonged ET, 
direct toxicity on hair follicles or both. 
Recent data suggest that ET-related alope-
cia may improve with topical minoxidil 5%. 
No data exist on the efficacy of topical 
minoxidil on patients taking CDK4/6i but, 
considering the proven effect of alopecia on 
emotions and self-confidence of patients 
with breast cancer, the panel recomended its 
prescription, as the compound has no hor-
monal properties (unlike finasteride), and no 
DDIs are expected.
Collaborative module
This module addresses the risk of interaction 
between palbociclib/ribociclib and other drugs 
eventually used as concomitant or adjuvant thera-
pies to CDK4/6i. It aims to provide a positive list of 
drugs that can be used safely in combination with 
Table 7. Incidence of other palbociclib/ribociclib toxicities according to clinicaltrials.gov.60,63,84
PALOMA-260 PALOMA-363 MONALEESA-284
 P + L L P + F F R + L L
Asthenia 16.9 11.7 6.7 4.6 12.9 11.52
Fatigue 37.4 27.5 37.9 26.7 36.5 30.0
Stomatitis 15.3 5.9 11.6 2.3 12.3 6.7
Rash 13.7 9.9 17.8 11.7 17.1 7.9
Pruritus 8.8 3.60 5.51 5.81 13.5 5.8
Tearing 5.6 0.9 < 5 < 5 6.89 1.82
Nausea 37.4 27.5 28.9 25.6 51.5 28.5
Vomiting 15.5 16.7 14.5 11.6 29 15
Decreased appetite 14.9 9.0 12.8 7.6 18.2 15.1
Dysgeusia 10.1 4.9 10.1 5.0 9.28 5.76
Gastric reflux 6.0 3.15 < 5 < 5 < 5 < 5
Diarrhoea 26.1 19.4 19 14.4 35 22
Constipation 19.4 15.3 16.8 13.9 22.16 19.1
Abdominal pain 11.3 5.4 5.2 6 9 7.6
Alopecia 32.8 15.8 14.8 5.8 33.2 15.5
Anaemia 23.2 9.01 25.51 9.88 17.66 4.55
Thrombocytopenia 9.91 0.9 11.59 0 5.69 0.61
L, letrozole; P, palbociclib; R, ribociclib.
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palbociclib or ribociclib for most of the more com-
mon concomitant conditions suffered by patients 
with MBC. Furthermore, oncologists are provided 
with an explanation as why some drugs are prohib-
ited (or should be used with caution), as well as a 
recommendation about regime adjustments.
In all sections, the following colour scheme has 
been used to grade the relative risk of each inter-
action: (a) green: low risk; orange: caution should 
be exercised; red: high risk.
Antibiotics, antivirals and antifungal 
medications: recommendations from the 
Specialists in Infectious Diseases
Patients with MBC often have some grade of 
immune suppression due to present or past CT, 
glucocorticoid treatment and, today, therapies 
with other drugs able to induce haematological 
toxicity, such as CDK 4/6i.
In pivotal trials, a slight increase in infection was 
observed when combining ET with palbociclib or 
ribociclib compared with ET + placebo. Only 
3–6% of infections reported were considered G3/
G4 (see also Table S6, Supplementary material, 
File 1).3–6,48,49,52 Most common infectious condi-
tions were urinary tract infections and pneumo-
nia, as reported in the general population.
According to this data, no special anti-infective 
prophylaxis is needed in patients with breast can-
cer taking CDK4/6i, otherwise considered immu-
nocompetent. This population must follow the 
data sheet management guidelines, including 
blood tests and dose interruptions/adjustments 
when required. However, prophylactic manage-
ment of infectious diseases must be considered in 
special circumstances.
 • HIV-positive patients. Patients who are 
known carriers of HIV were excluded from 
CDK4/6i trials, but there are no reasons to 
suspect that HIV patients will not benefit 
from these drugs or that they will have more 
severe toxicities provided that the HIV is 
under control with adequate treatment. In 
fact, a recent preclinical study has described 
a possible role for palbociclib in HIV treat-
ment by blocking the HIV-1 reverse tran-
scription,92 which, if confirmed, may 
provide an additional reason to introduce 
palbociclib in those patients sharing both 
conditions (breast cancer and HIV 
positivity). In all HIV+ patients for whom 
treatment with CDK4/6i is planned, close 
monitoring by the infectious disease spe-
cialist before and during treatment is man-
datory. In patients with uncontrolled HIV 
infection, additional immune suppression 
using CDK4/6i could cause severe compli-
cations, and must be avoided until safety 
data supporting it has been obtained.
 • Glucocorticoid treatment. Patients treated 
with glucocorticoids were not specifically 
excluded from pivotal trials with CDK4/6i, 
but in general this therapy was limited to low 
doses and/or a short period of time. Outside 
the clinical trial setting, patients receive long 
or more intensive glucocorticoid courses, so 
a higher level of immune suppression with 
concomitant CDK4/6i is anticipated. In this 
context, it is especially relevant to introduce 
chemoprophylaxis for Pneumocystis jirovecii. 
According to National Comprehensive 
Cancer Network (NCCN) guidelines, 
patients receiving over 20 mg of prednisone/
day for more than 4 weeks (or an equivalent 
dose of other corticoids) should begin tri-
methoprim-sulfamethoxazole (TMP/SMX) 
at prophylactic doses (800/160 mg twice a 
week, 800/160 mg daily or 400/80 mg 
daily).93 TMP/SMX must be used with cau-
tion, particularly with ribociclib, when ther-
apeutic doses are used, because concomitant 
CDK4/6i can increase bioavailability of 
TMP/SMX, therefore increasing the risk of 
medullar toxicity. However, at a prophylac-
tic dosage, no DDIs are expected. 
Prophylactic TMP/SMX should also be 
considered in patients with prolonged lym-
phopenia, irrespective of treatment with cor-
ticoids, since they are also at risk of presenting 
with P. jirovecii pneumonia.
 • Chronic carriers of HBV. There are no spe-
cific safety data for HBV carriers treated 
with palbociclib or ribociclib. In patients 
with breast cancer who are receiving CT, 
the prophylaxis of HBV reactivation has 
shown efficacy.94 Although the introduc-
tion of lamivudine has been demonstrated 
to be useful in preventing HBV reactivation 
in this setting,95 better results have been 
recently obtained with tenofovir and enta-
cavir.96,97 Based on these data, the authors 
recommended initiating prophylaxis treat-
ment in chronic carrier patients of HBV 
infection (positive HBsAg or HBV DNA) 
when it is planned to treat them with 
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CDK4/6i. This recommendation also takes 
into account that no DDIs between tenofo-
vir, entacavir or lamivudine and CDK 4/6i 
are expected.
According to the workshop’s objectives, the panel 
elaborated a list of anti-infective agents categorized 
by risk of pharmacokinetic interactions and poten-
tial synergy for QTc prolongation (Table 8).
Drugs for the prevention and treatment of 
digestive symptoms and antihistamine drugs
Digestive toxicity is commonly associated with pal-
bociclib or ribociclib treatment (see tables in educa-
tional module, “Reflecting on liver toxicity: 
Incidence and management. Who is at risk?” sec-
tion and Supplementary material, File 1). In the 
PALOMA-23 and PALOMA-3 trials,6 a similar 
proportion of all-grade nausea (35% and 32%, 
respectively), diarrhoea (26% and 25%, respec-
tively), constipation (19% in both studies) and 
vomiting (15% and 17%, respectively) were 
described in the palbociclib arm. Moreover, 9% and 
4% of women had dyspepsia in these studies. All 
these digestive toxicities were more frequent than in 
the corresponding control arm. However, almost all 
of them were reported as G1 or G2, and most did 
not require medical treatment. With ribociclib, and 
regarding all-grade toxicity, nausea (51%, 45% and 
31%, respectively), diarrhoea (35%, 29% and 19%, 
respectively), vomiting (29%, 26% and 18%, 
respectively) and constipation (25%, 15% and 16%, 
respectively) were described in the MONALEESA-3 
trial.4,49,52 Almost all were G1/G2 toxicities, and 
some required pharmacological intervention.
Both the palbociclib and ribociclib studies3,4,6,49,52 
described an overall 17% of all-grade rash inci-
dence, 14–17.8% (palbociclib) and 13–18% 
(ribociclib), most of them G1/G2, and sometimes 
requiring treatment with antihistamine drugs. 
All-grade pruritus has also been frequently 
reported in the MONALEESA trials, with inci-
dences ranging between 9% and 19%, mostly 
considered to be G1/G2.
In this section, potential DDIs between palboci-
clib and ribociclib and common drugs used for 
treating digestive symptoms (i.e. antiemetics, 
prokinetics, antacids, gastric mucosal protective 
drugs, antidiarrhoeals and laxatives), together 
with antihistamine drugs have been reviewed 
(Table 9). As in previous sections, the drugs con-
sidered safe options are listed for all indications.
Drugs for endocrine and cardiovascular 
disorders
In this section, potential DDIs between available 
CDK4/6i and some of the most common drugs 
used in the treatment of dyslipidaemia, diabetes 
and cardiovascular disorders, including antiplate-
let drugs and anticoagulants, were examined.
Regarding antihypertensive drugs (Table 10) and 
compounds used to treat congestive heart failure, 
most palbociclib and ribociclib DDIs occur via 
CYP3A4, with increased risk for ribociclib due to 
its pharmacokinetic properties (see “Drug meta-
bolic pathways and membrane transporters: How 
to interpret drug-drug interactions with palbociclib 
and ribociclib?” section in the educational mod-
ule). Angiotensin II receptor antagonists (except-
ing losartan), angiotensin-converting-enzyme 
inhibitors, beta blockers (excepting bisoprolol), 
potassium-sparing diuretics (excepting eplenorone) 
and torsemide are considered safe options. Other 
commonly used loop diuretics should be adminis-
tered with caution due to their conditional risk of 
TdP. Calcium-channel blockers are major sub-
strates for CYP3A4 and, at the same time, moder-
ate inhibitors, hence, clinically relevant DDIs with 
palbociclib, and particularly with ribociclib, are 
expected and, subsequently, concomitant admin-
istration should be avoided. Losartan and 
eplenorone, as well as other major substrates for 
CYP3A4, are not recommended. Bisoprolol 
should also be avoided since, besides being a major 
substrate for CYP3A4, it has an NTI; its potential 
risk for TdP is being investigated.31
Regarding antidiabetics drugs (Table 11) some 
of the DDIs described with palbociclib and ribo-
ciclib result from competition for the membrane 
transporters. Therefore, biguanides (metformin) 
and some sodium-glucose cotransporter 2 
(SGLT2) inhibitors (e.g. canagliflozin, capagli-
fozin) must be administered with caution if con-
comitantly used with these CDK4/6i; in these 
cases, glycaemia should be carefully monitored. 
Meglitinides and repaglinide, also SGLT2 inhib-
itors, should be avoided, as well as saxagliptin 
and linagliptin (dipeptidyl peptidase 4 inhibitors 
[DPP-4i]). The latter may also interact with pal-
bociclib and ribociclib via membrane transport-
ers but they are, first and foremost, major 
substrates of CYP3A4. By contrast, sulfonylu-
reas, alpha-glucosidase inhibitors, glucagon-like 
peptide-1 receptor agonists and other DPP-4i, 
namely vildagliptin, alogliptin and sitagliptin, 
can be safely administered.
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Table 10. Drugs for treatment of hypertension and congestive heart failure: Categorization according to their risk of DDIs and QTc 
prolongation when used concomitantly with ribociclib and palbociclib.
Antihypertensives CYP3A4
Substrate
CYP3A4
Inhibitor
CYP3A4 
Inducer
Membrane 
transporter 
substrate
TdP risk Comments
ARA-II antagonists 
Candesartan
Eprosartan
 Irbesartan
Olmesartan
Telmisartan
 Valsartan
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Not Known
Not Known
Not Known
Not Known
Not Known
Not Known
Low risk of interaction with 
palbociclib and ribociclib
SAFE OPTIONS
ACE inhibitors
Enalapril
Captopril
Fosinopril
Ramipril
Quinapril
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Not known
Not Known
Not Known
Not Known
Not Known
Low risk of interaction with 
palbociclib and ribociclib
SAFE OPTIONS
Beta blockers
Atenolol
Metoprolol
Nadolol
Pindolol
Labetalol
Propranolol
Carvedilol
–
–
–
–
–
Minor
Minor
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Not Known
Not Known
Not Known
Not Known
Not Known
Not Known
Not Known
Low risk of interaction with 
palbociclib and ribociclib
SAFE OPTIONS
Calcium channel 
blockers:
Dihydropyridines
Clevidipine – – – – Not Known
Low risk of interaction with 
palbociclib and ribociclib
SAFE OPTIONS
Diuretics:
Potassium sparing 
diuretics:
 Amiloride
Triamterene 
Spironolactone
–
–
–
–
–
–
–
–
–
–
–
–
Not known
Not known
Not known
Low risk of interaction with 
palbociclib and ribociclib
SAFE OPTIONS
Diuretics:
Loop diuretics
Torsemide
Furosemide
Hydrochlorothiazide
Indapamide
–
–
–
–
–
–
–
–
–
–
–
–
OATP1B1
OAT3
–
–
Conditional
Conditional
Conditional
Conditional
Low risk of interaction with 
palbociclib
SAFE OPTIONS
Diuretics:
Loop diuretics
Torsemide
Furosemide
Hydrochlorothiazide
Indapamide
–
–
–
–
–
–
–
–
–
–
–
–
OATP1B1
OAT3
–
–
Conditional
Conditional
Conditional
Conditional
Caution should be exercised in 
combination with ribociclib
ARA- II antagonists:
Losartan Major, NTI – – – Not known
High risk of DDIs.
Should be avoided the 
combination
with ribociclib or palbociclib
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Antihypertensives CYP3A4
Substrate
CYP3A4
Inhibitor
CYP3A4 
Inducer
Membrane 
transporter 
substrate
TdP risk Comments
Potassium sparing 
diuretics:
Eplerenone
Major, 
sensitive
– – – Not known
High risk of DDIs.
Should be avoided the 
combination
with ribociclib or palbociclib
Beta blockers:
Bisopropol1 Major, NTI – – – Not known
High risk of DDIs.
Should be avoided the 
combination with ribociclib or 
palbociclib
Calcium channel 
blockers:
Dihydropyridines
Amlodipine
Barnidipine
Felodipine
Lacidipine
Lercadipine
Manidipine
Nifedipinde
Nimodipino
Nisoldipine
Nitrendipine
Nicardipine
Non dihydropyridines:
Verapamil
Diltiazem
Major
Major
Major
Major
Major
Major
Major
Major
Major
Major
Major
Major
Major
–
–
–
–
–
–
Moderate
–
–
–
Moderate
Moderate
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
gp-P
gp-P
Not Known
Not Known
Not Known
Not Known
Not Known
Not Known
Not Known
Not Known
Not Known
Not Known
Possible
Not known
Not Known
High risk of DDIs.
Should be avoided the 
combination with ribociclib or 
palbociclib
Green: Low risk of interaction with palbociclib and ribociclib, SAFE OPTIONS. Orange: Caution should be exercised. Red: High risk of DDIs. 
Plasmatic concentrations of the CYP3A4 substrate could be increased (or decreased) when used concomitantly with a CYP3A4 inhibitor (or inducer) 
moderate or strong. ARA-II: angiotensin II receptor blockers; ACE inhibitor: angiotensin-converting enzyme inhibitors NTI: narrow therapeutic 
index. TdP,Torsades de pointes; gp-P, P-glycoprotein; OATP1B1, organic anion transporter polypeptide; OAT3, organic anion transporter.
1 Not classified risk QT. According to the source consulted (www.crediblemeds.org), the evidence available at this time did not result in a decision 
for it to be placed in any of the four QT risk categories.
Table 10. (Continued)
Palbociclib and ribociclib can interact with some 
statins via time-dependent inhibition of CYP3A4, 
in particular with simvastatin and atorvastatin 
(Table 12). Therefore, side effects and response 
to both drugs should be closely monitored if con-
comitantly used. One case of fatal rhabdomyoly-
sis after initiation of palbociclib-fulvestrant 
initiation in a woman receiving atorvastatin has 
been reported.31 Safer alternatives are pitavasta-
tin, rosuvastatin or pravastatin.
Finally, most antiplatelet and anticoagulant 
drugs do not have relevant DDIs with 
palbociclib and ribociclib (Table 13). The few 
DDIs described are metabolic in nature, via 
CYP3A4 metabolism or membrane transport-
ers. Exceptionally, cilostazol, an antiplatelet 
drug, has known TdP risk, hence it is not rec-
ommended and should be particularly avoided 
with ribociclib.
Analgesics and opioids
Pain control represents one of the greatest chal-
lenges in patients with cancer. It is one of the 
most common symptoms associated with cancer, 
affecting up to 64% of patients with advanced 
disease.99 According to the International 
Association for the Study of Pain, pain prevalence 
in breast cancer varies from 40% to 89%.100 When 
prescribing analgesics, side effects and DDIs with 
other medications must be taken into account. 
Therapies for pain must be integrated into the 
patient’s oncological management.101
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Table 11. Drugs for treatment of diabetes: Categorization according to their risk of DDIs and QTc prolongation when used 
concomitantly with ribociclib and palbociclib.
Antidiabetics CYP3A4
Substrate
CYP3A4
Inhibitor
CYP3A4 
Inducer
Membrane 
transporter 
substrate
TdP risk Comments
Sulfonylureas:
Glicazide
Glibenclamide
Glisentide
Glipizide
Gliquidone
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
OATP1B1
OATP1B3
–
OATP1B3
–
Not known
Not known
Not known
Not known
Not known
Low risk of interaction with 
palbociclib and ribociclib SAFE 
OPTIONS
Alfa glycosidase 
inhibitors:
Ascarbose
Miglitol
–
–
–
–
–
–
Not known
Not known
GLP-1:
Albiglutide
Dulaglutide
Exenatide
Liraglutide
lixisenatide
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Not known
Not known
Not known
Not known
Not known
DPP-4 inhibitor:
Vildagliptin
Alogliptin
Sitagliptin
–
Minor
–
–
–
–
–
–
–
–
–
gp-P
Not known
Not known
Not known
SGLT2 inhibitor:
Canagliflozin
Dapagliflozin
Minor
–
–
–
–
–
gp-P
gp-P
Not known
Not known
Biguanides:
Metformin – – – OCT2, OCT1, 
MATE 1/2
Not known Caution should be exercised in 
combination with ribociclib or 
palbociclib
Meglitinides:
Repaglinide Major – – OATP1B1/1B3 Not known High risk of DDIs.
Should be avoided the 
combination
with ribociclib or palbociclib
DPP-4 inhibitor:
Saxagliptin
Linagliptin
Major
Major
–
–
–
–
gp-P
gp-P
Not known
Not known
Green: Low risk of interaction with palbociclib and ribociclib, SAFE OPTIONS. Orange: Caution should be exercised. Red: High risk of DDIs. 
Plasmatic concentrations of the CYP3A4 substrate could be increased (or decreased) when used concomitantly with a CYP3A4 inhibitor 
(or inducer) moderate or strong. GLP-1: Glucagonlike-peptide 1; SGLT2: Sodium -glucosecotransporter 2; DPP-4: dipeptidylpeptidase IV; 
TdP,Torsades de pointes; gp-P, P-glycoprotein; OATP1B1, organic anion transporter polypeptide; OCT2, OCT1 organic cation transporter 1 and 2; 
MATE 1/2, multidrug and toxin extrusion 1 and 2
According to the PALOMA-1 trial pain assess-
ment, the addition of palbociclib to the letrozole 
treatment had no impact on pain control, 
although results were not adjusted for the con-
comitant use of opioids and other analgesic med-
ications.102 In the MONALEESA-2 study, a 
trend was observed favouring ribociclib + letro-
zole for pain reduction.103
Taking into account a potential DDI with pal-
bociclib and ribociclib, the metabolism profile 
and QTc-prolongation risk of the most fre-
quently used drugs for pain control were 
reviewed and classified by drug interaction risk 
potential (see Tables 14–16 for non-opioid 
analgesics, opioid analgesics and adjuvants/anti-
convulsants, respectively).
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Table 12. Lipid-lowering drugs categorized according to their risk of DDIs and QTc prolongation when used concomitantly with 
ribociclib and palbociclib.
Lipid-lowering CYP3A4
Substrate
CYP3A4
Inhibitor
CYP3A4 
Inducer
Membrane 
transporter 
substrate
TdP risk Comments
Statins:
Pitavastatin1 – – – OATP1B1/1B3 Not known Low risk of interaction 
with palbociclib and 
ribociclib.
SAFE OPTIONS
Fibrates:
Fenofibrate1
Gemfibrozil
–
Minor
–
–
–
–
–
–
Not known
Not known
Statins:
Fluvastatin Minor – – OATP1B1/1B3 Not known
Caution should 
be exercised in 
combination with 
ribociclib or palbociclib
Pravastatin1 Minor – – OATP1B1/1B3, 
OAT1/OAT3
Not Known
Rosuvastatin1 Minor – – OATP1B1/1B3, 
BCRP
Not known
Statins:
Simvastatin1 Major/
sensitive
– – OATP1B1/1B3 Not known
High risk of DDIs.
Should be avoided the 
combination
with ribociclib or 
palbociclib
Atorvastatin Major/mode-
rate sensitive
– – OATP1B1/1B3,
gp-P
Not known
Green: Low risk of interaction with palbociclib and ribociclib, SAFE OPTIONS. Orange: Caution should be exercised. Red: High risk of DDIs. 
Plasmatic concentrations of the CYP3A4 substrate could be increased (or decreased) when used concomitantly with a CYP3A4 inhibitor (or 
inducer) moderate or strong. TdP,Torsades de pointes; gp-P, P-glycoprotein; OATP1B1/3, organic anion transporter polypeptide; OAT1/3, organic 
anion transporter 1 and 3; OCT2/1 organic cation transporter 1 and 2 ; BCRP, breast cancer resistance protein.
1 According to the source consulted (www.crediblemeds.org), the drug is under active review for possible risk of QT prolongation and torsades de 
pointes.
Antidepressants and antipsychotics
The risk of concomitant treatments with palboci-
clib/ribociclib and antidepressants, antipsychotic, 
and anxiolytic/hypnotic drugs is summarized in 
Tables 17–19, respectively.
Complementary alternative medicine
A large and not well-known proportion of patients 
with breast cancer use alternative and comple-
mentary medicine. There are reports of preva-
lence of use in up to 87% of patients.108,109
Some alternative and complementary preparations 
have shown efficacy in preclinical studies, but have 
not demonstrated relevant anticancer effects in the 
clinical setting. However, patients actually use 
these preparations and some are reluctant to aban-
don them when beginning CDK4/6i therapy.
Overall, there is scarce information about poten-
tial DDIs with these complementary compounds. 
There are huge amounts of these formulations, so 
a comprehensive review of all of them was not 
possible. The most used alternative preparations 
in our immediate environment were addressed at 
the workshop,. The most relevant conclusions are 
shown in Table 20.
An important consideration is that there are 
many different formulations, doses, schemes 
and routes of administration for these drugs or 
foods, making it impossible, in many cases, to 
set forth general recommendations by type of 
product. For example, green tea extract can 
inhibit CYP3A4 in a range that varies from 
5.6% to 89.9%. In this case, taking a green tea 
infusion some days will not have any relevant 
risk for CDK4/6i-treated patients, but those 
treated with Natrol™ 500 mg,108 will be at high 
risk of enhanced CDK4/6i toxicity. Treatments 
affected by this important consideration are 
accompanied with the statement ‘Use with cau-
tion’ in Table 20, and patients should be advised 
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Table 14. Non-opioid analgesics categorized according to their risk for DDIs and QTc prolongation when used concomitantly with 
ribociclib or palbociclib.
Non-opioid analgesics CYP3A4
Substrate
CYP3A4
Inhibitor
CYP3A4 
Inducer
Membrane 
transporter 
substrate
TdP risk[31] Comments
AAS1
Metamizole
Aceclofenac
Indomethacin
Ketorolac
Piroxicam1
Tenoxicam
Dexketoprofen
Flurbiprofen
Ibuprofen1,2
Sulindac
Naproxen1,3
Mephenamicacid
Acetaminophen2
Diclofenac
Meloxicam
Celecoxib2
Etoricoxib
–
–
–
–
–
–
–
–
–
–
–
–
–
Minor
Minor
Minor
Minor
minor
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Not known
Not known
Not known
Not known
Not known
Not known
Not known
Not known
Not known
Not known
Not known
Not known
Not known
Not known
Not known
Not known
Not known
Not known
Low risk of interaction with 
palbociclib and ribociclib
SAFE OPTIONS
Parecoxib Major – – – Not known Caution should be exercised in 
combination with ribociclib or 
palbociclib
Ergotamine
Dihydro-ergotamine
Major, NTI –
–
–
–
–
–
Not known
Not known
High risk of DDIs.
Should be avoided the 
combination
with ribociclib or palbociclib
Green: Low risk of interaction with palbociclib and ribociclib, SAFE OPTIONS. Orange: Caution should be exercised. Red: High risk: Plasmatic 
concentrations of the substrate could be increased when used concomitantly with a CYP3A4 inhibitor, such as palbociclib (weak) or ribociclib 
(moderate-potent). Risk of increased toxicity. NTI: narrow therapeutic index
1 It can inhibit MRP-2 and MRP-4 renal transporters. Interaction of non-steroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 
2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport [104].
2 Not classified risk QT. According to the source consulted (www.crediblemeds.org), the evidence available at this time did not result in a decision 
for it to be placed in any of the four QT risk categories.
3 According to the source consulted (www.crediblemeds.org), the drug is under active review for possible risk of QT prolongation and torsades de 
pointes.
Table 15. Opioid analgesics categorized according to their risk for DDIs and QTc prolongation when used concomitantly with 
ribociclib or palbociclib.
Opioid analgesics CYP3A4
Substrate
CYP3A4
Inhibitor
CYP3A4Inducer Membrane 
transporter 
substrate
TdP risk Comments
Morphine
Hydromorphone
Tapentadol
Codeine
–
–
–
Minor
–
–
–
–
–
–
–
–
P-gp*
–
–
–
Not known
Not known
Not known
Not known
Low risk of interaction 
with palbociclib and 
ribociclib
SAFE OPTIONS
Tramadol
Buprenorphine
Oxycodone
Major
Major
Major
–
–
–
–
–
–
–
–
–
Possible
Possible
Not known
Caution: risk of 
increased toxicity of 
the substrate
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Opioid analgesics CYP3A4
Substrate
CYP3A4
Inhibitor
CYP3A4Inducer Membrane 
transporter 
substrate
TdP risk Comments
Methadone
Fentanyl‡
Major
Major NTI
–
–
–
–
–
–
Known risk$
Not known
High risk of DDIs. 
Should be avoided the 
combination
with ribociclib or 
palbociclib
Green: Low risk of interaction with palbociclib and ribociclib, SAFE OPTIONS. Orange: Caution should be exercised. Red: High risk: Plasmatic 
concentrations of the substrate could be increased when used concomitantly with a CYP3A4 inhibitor, such as palbociclib (weak) or ribociclib 
(moderate-potent). Risk of increased toxicity. NTI: narrow therapeutic index.
* In vitro data suggest that palbociclib and ribociclib may inhibit P-glycoprotein (P-gp) and that inhibition may increase exposition to substrates, but 
there is no in vivo evidence of this interaction.
$QTc interval prolongation risk of the CYP3A4 substrate can be increased as a consequence of the metabolic inhibition (substrate accumulation).
‡ If fentanyl cannot be changed when starting treatment with palbociclib or ribociclib, consider reducing the dose and closely monitoring for side effects.
Table 15. (Continued)
Table 16. Adjuvants and anticonvulsants categorized according to their risk for DDIs and QTc prolongation when used concomitantly 
with ribociclib or palbociclib.
Adjuvants and 
anticonvulsants
CYP3A4
Substrate
CYP3A4
Inhibitor
CYP3A4
Inducer
Membrane 
transporter 
substrate
TdP risk Comments
Pregabalin1
Gabapentin1
Levetiracetam1
Lamotrigine1
Topiramate1
Baclofen1
Clonidine1
Octreotide1
Alendronate1
Zoledronate
Denosumab
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Not known
Not known
Not known
Not known
Not known
Not known
Not known
Not known
Not known
Not known
Not known
Low risk of interaction with 
palbociclib and ribociclib
SAFE OPTIONS
Lacosamide1
Valproic acid1
Prednisone2
Methylprednisolone2
Hydrocortisone
Dextromethorphan
Minor
Minor
Minor
Minor
Minor
Minor
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
P-gp
–
Not known
Not known
Not known
Not known
Not known
Not known
Dexamethasone Major – Weak 3 P-gp Not known
Caution should be exercised in 
combination with ribociclib or 
palbociclib
Zonisamide Major – – – Not known
Oxcarbazepine – – Weak – Not known
Ketamine Major – – – Not known
Carbamazepine Major – Strong – Not known
High risk of DDIs. Should be 
avoided the combination
with ribociclib or palbociclib
Phenobarbital – – Strong – Not known
Phenytoin Minor – Strong – Not known
Green: Low risk of interaction with palbociclib and ribociclib, SAFE OPTIONS. Orange: Caution should be exercised. Red: High risk of DDIs. 
Plasmatic concentrations of the CYP3A4 substrate (palbociclib or ribociclib) could be decreased when used concomitantly with a CYP3A4 inducer 
moderate or strong. TdP,Torsades de pointes; gp-P, P-glycoprotein.
1 Not classified risk QT. According to the source consulted (www.crediblemeds.org), the evidence available at this time did not result in a decision 
for it to be placed in any of the four QT risk categories.
2 According to the source consulted (www.crediblemeds.org), the drug is under active review for possible risk of QT prolongation and torsades de pointes
3Dexamethasone is a CYP3A4 inducer weak-moderate. Risk of decreasing levels of palbociclib or ribociclib by metabolism induction
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Table 17. Antidepressants categorized according to their safety as concomitant treatment with palbociclib and ribociclib.
Antidepressants CYP3A4
Substrate
CYP3A4
Inhibitor
CYP3A4 
Inducer
Membrane 
transporter 
substrate
TdP risk Comments
Duloxetine1 – – – – Not known Low risk of interaction with 
palbociclib and ribociclib
SAFE OPTIONS
Desvenlafaxine
Vortioxetine2
Minor
Minor
–
–
–
–
–
–
Not known
Not known
Paroxetine1 – – – – Conditional Caution should be exercised 
in combination with ribociclib 
or palbociclib
Sertraline1
Fluoxetine1,3
Minor
Minor
–
–
–
–
–
–
Conditional
Conditional
Trazodone Major – – – Conditional
High risk of DDIs. Should be 
avoided the combination
with ribociclib or palbociclib
Mirtazapine
Venlafaxine
Major
Major
–
–
–
–
–
–
Possible
Possible
Citalopram
Escitalopram
Major, NTI
Major, NTI
–
–
–
–
–
–
Known
Known
Green: Low risk of interaction with palbociclib and ribociclib, SAFE OPTIONS. Orange: Caution should be exercised. Red: High risk: Plasmatic 
concentrations of the substrate could be increased when used concomitantly with a CYP3A4 inhibitor, such as palbociclib (weak) or ribociclib 
(moderate-potent). Risk of increased toxicity. NTI, narrow therapeutic index; SPC, Summary of Product Characteristics; TdP, torsades de pointes.
1 Fluoxetine and paroxetine are strong CYP2D6 inhibitors; duloxetine is moderate CYP2D6 inhibitors; and sertraline is a weak CYP2D6 inhibitor. 
Concomitant use with tamoxifen should be avoided.
2 Controversial data. The Summary of Product Characteristics[105] and other authors [106] categorize Vortioxetine as a major substrate of CYP2D6 
and a minor substrate of CYP3A4. For Uptodate® [107], vortioxetine is a major substrate for CYP2D6 and CYP3A4.
3Fluoxetine has a longer half-life.
Table 18. Antipsychotic drugs categorized according to their safety as concomitant treatment with palbociclib and ribociclib.
Antipsychotic CYP3A4
Substrate
CYP3A4
Inhibitor
CYP3A4 
Inducer
Membrane 
transporter 
substrate
TdP risk Comments
Amisulpride1
Olanzapine1
–
–
–
–
–
–
–
–
Conditional
Conditional
Low risk of interaction with 
palbociclib
SAFE OPTIONS
Amisulpride1
Olanzapine1
–
–
–
–
–
–
–
–
Conditional
Conditional
Caution should be exercised in 
combination with ribociclib
Paliperidone – – – – Possible
Caution should be exercised in 
combination with ribociclib or 
palbociclib
Risperidone
Asenapine
Perphenazine
Clozapine
Minor
Minor
Minor
Minor
–
–
–
–
–
–
–
–
–
–
–
–
Possible
Possible
Possible
Possible
Quetiapine2 Major NTI – – – Conditional
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Antipsychotic CYP3A4
Substrate
CYP3A4
Inhibitor
CYP3A4 
Inducer
Membrane 
transporter 
substrate
TdP risk Comments
Sulpiride – – – – Known
High risk of DDIs. Should be 
avoided the combination
with ribociclib or palbociclib
Chlorpromazine
levomepromazine
Minor
Minor
–
–
–
–
–
–
Known
Known
Ziprasidone Minor Moderate – – Conditional
Aripiprazole Major – – – Possible
Haloperidol Major – – – Known
Pimozide Major NTI – – – Conditional
Green: Low risk of interaction with palbociclib and ribociclib, SAFE OPTIONS. Orange: Caution should be exercised. Red: High risk: Plasmatic 
concentrations of the substrate could be increased when used concomitantly with a CYP3A4 inhibitor, such as palbociclib (weak) or ribociclib 
(moderate-potent). Risk of increased toxicity. NTI, narrow therapeutic index; TdP, torsades de pointes.
1 Amisulpride and olanzapine are associated with Conditional Risk of TdP, but this risk is dose-dependent. Both drugs are probably safe at a 
therapeutic dose.
2Quetiapine is mainly prescribed for elderly patients at low doses as anxiolytic.
Table 18. (Continued)
Table 19. Anxiolytics and hypnotics categorized according to their safety as concomitant treatment with palbociclib and ribociclib.
Anxiolytics and 
hypnotics
CYP3A4
Substrate
CYP3A4
Inhibitor
CYP3A4 
Inducer
Membrane 
transporter 
substrate
TdPrisk Comments
Lorazepam1
Lormetazepam1
Clotiazepam1
–
–
–
–
–
–
–
–
–
–
–
–
Not known
Not known
Not known
Low risk of 
interaction with 
palbociclib and 
ribociclib
SAFE OPTIONSBromazepam1 Minor – – – Not known
Clobazam Minor – Weak – Not known
Diazepam1
Clorazepate1
Clonazepam1
Midazolam1
Flurazepam1
Major
Major
Major
Major
Major
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Not known
Not known
Not known
Not known
Not known
Caution should 
be exercised 
in combination 
with ribociclib or 
palbociclib
Alprazolam1 Major Weak – – Not known
Zolpidem1
Zopiclone1
Major
Major
–
–
–
–
–
–
Not known
Not known
Green: Low risk of interaction with palbociclib and ribociclib, SAFE OPTIONS. Orange: Caution should be exercised. TdP, Torsades de pointes.
1 Not classified risk QT. According to the source consulted (www.crediblemeds.org), the evidence available at this time did not result in a decision for 
it to be placed in any of the four QT risk categories.
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to avoid them. If, despite this recommendation, 
a patient still wants to take it, a careful evalua-
tion of the dosage is needed before prescribing 
palbociclib or ribociclib.
Preparations in green in Table 20 do not show an 
important risk of drug interaction, but are not 
necessarily safe or a good option for cancer treat-
ment. Being classified as a safe preparation only 
implies a low risk of interaction.
Conclusion
The Spanish SOLTI-promoted workshop enti-
tled ‘CDK4/6 Inhibitors in Breast Cancer: 
Consensus Workshop on the Management of 
Concomitant Medication’ gathered profession-
als from different specialties to address key ques-
tions related to the management of palbociclib 
and ribociclib, the two CDK4/6 inhibitors 
approved in Spain. The issues raised in this 
1-day meeting included a comprehensive review 
of some selected toxicities and the mechanisms 
underlying potential DDIs. The ultimate goal 
was to elaborate ‘positive lists’ of medications 
that could be safely administered concomitantly 
with palbociclib and ribociclib.
As a result, lists of safe drugs or groups of drugs 
are provided, These positive lists comprise a total 
of 273 drugs belonging to 18 families, and 
include anti-infective agents, psychotropic drugs, 
analgesics, anticonvulsants and drugs to treat 
endocrine and cardiovascular disorders. In addi-
tion, when possible, the reason why a substantial 
number of concomitant medications must be 
used with caution or are totally prohibited in 
combination with palbociclib and ribociclib is 
clearly established. A safety evaluation for the 
most requested complementary and alternative 
medicines (18 compounds) is also attempted, in 
spite of the scarcity of evidence for this setting. 
The panel felt that all this information will be 
extremely useful in the oncologist’s daily practice 
and hope that it will result in a safer management 
of patients with luminal MBC.
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